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Abstract Epoxide hydrolases catalyse the hydrolysis of
electrophilic—and therefore potentially genotoxic—epox-
ides to the corresponding less reactive vicinal diols, which
explains the classiWcation of epoxide hydrolases as typical
detoxifying enzymes. The best example is mammalian
microsomal epoxide hydrolase (mEH)—an enzyme prone
to detoxiWcation—due to a high expression level in the
liver, a broad substrate selectivity, as well as inducibility by
foreign compounds. The mEH is capable of inactivating a
large number of structurally diVerent, highly reactive epox-
ides and hence is an important part of the enzymatic
defence of our organism against adverse eVects of foreign
compounds. Furthermore, evidence is accumulating that
mammalian epoxide hydrolases play physiological roles
other than detoxiWcation, particularly through involvement
in signalling processes. This certainly holds true for soluble
epoxide hydrolase (sEH) whose main function seems to be
the turnover of lipid derived epoxides, which are signalling
lipids with diverse functions in regulatory processes, such
as control of blood pressure, inXammatory processes, cell
proliferation and nociception. In recent years, the sEH has
attracted attention as a promising target for pharmacologi-
cal inhibition to treat hypertension and possibly other
diseases. Recently, new hitherto uncharacterised epoxide
hydrolases could be identiWed in mammals by genome
analysis. The expression pattern and substrate selectivity of
these new epoxide hydrolases suggests their participation in
signalling processes rather than a role in detoxiWcation.
Taken together, epoxide hydrolases (1) play a central role
in the detoxiWcation of genotoxic epoxides and (2) have an
important function in the regulation of physiological pro-
cesses by the control of signalling molecules with an epox-
ide structure.
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Introduction
Epoxide hydrolases (EC 3.3.2.7-11) catalyse the hydrolysis
of epoxides to the corresponding vicinal diols by the addi-
tion of water. Xenobiotic derived epoxides can be formed
within the body as reactive intermediates during metabolic
processes by monooxygenation of carbon double bonds in
oleWnes or aromatic ring systems. Based on the ring tension
of such cyclic compounds in combination with a polarisa-
tion of the CO bond, epoxides often show electrophilic
reactivity leading to a certain genotoxic potential (Fig. 1a).
Two mammalian enzymes—microsomal (mEH) and solu-
ble epoxide hydrolase (sEH)—that classically play a major
role in xenobiotic metabolism have been intensely charac-
terised. Apart from a few exceptions the hydrolysis of an
epoxide results in an increased water solubility of the
metabolites and the termination of its genotoxic potential.
Therefore mammalian epoxide hydrolases, in particular the
mEH with its exceptionally broad substrate selectivity
against a diverse group of epoxides, perfectly serve their
function as xenobiotic metabolising enzymes (Fig. 1b).
This picture, however, needs some adjustment. It is now
well established that the organism utilises a large number of
endogenous epoxides—in particular epoxides derived from
unsaturated fatty acids, such as epoxyeicosatrienoic acid
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(EETs) and leukotriene A4 (LTA4)—as signalling mole-
cules. Due to their low chemical reactivity, these epoxides
have little genotoxic potential, but instead serve as impor-
tant signalling molecules, regulating a large variety of
physiological functions, ranging from the regulation of vas-
cular tone, to inXammation, angiogenesis and pain. Human
sEH, which is highly expressed throughout the body, is to
date regarded as the primary enzyme in the metabolism of
such endogenous epoxides (Fig. 1b). Our recently discov-
ered phosphatase activity of human sEH further highlights
the role of this enzyme in regulatory processes rather than
xenobiotic metabolism. Yet, it also serves a complementary
function to mEH in xenobiotic metabolism due to the
acceptance of certain trans-substituted epoxides.
Apart from the two well analysed EHs additional mam-
malian epoxide hydrolases contribute to the metabolism of
epoxides. Both sEH and mEH show an overall low
sequence homology but both belong to the family of /
hydrolase fold enzymes, based on structural similarities.
Using common structural elements of the / hydrolase
fold, candidate enzymes from the mammalian genomes
may be identiWed representing potential epoxide hydro-
lases. Our group has recently cloned and expressed two
such genes that we name epoxide hydrolase 3 (EH3) and 4
(EH4) (manuscript in preparation) from the human genome.
Furthermore, the product of the peg1/MEST gene was
already in 1995 predicted to represent an / hydrolase fold
epoxide hydrolase (Kaneko-Ishino et al. 1995). The physio-
logical functions of these novel (potential) epoxide hydro-
lases in xenobiotic metabolism and/or lipid signalling still
needs to be determined.
Additional epoxide hydrolases with narrow substrate
selectivity—and therefore an unlikely role in xenobiotic
metabolism—have been characterised in mammals, based
on their enzymatic functions. Of those, mammalian leuko-
triene A4 hydrolase (LTA4H), which is involved in the turn-
over of the lipid mediator LTA4 to LTB4, is best
characterised (Haeggstrom 2004). LTA4 hydrolase does not
belong to the / hydrolase fold enzyme family but instead
represents a zinc dependant metalloprotease, which—as an
exception compared to all other EHs—forms a non-vicinal
diol from its substrate. Less well-investigated are Hepoxilin
A3 epoxide hydrolase and cholesterol epoxide hydrolase
(ChEH) which were identiWed as the main hydrolase of the
endogenous lipids hepoxilin A3 (Pace-Asciak and Lee
1989) and cholesterol-5,6-epoxide (Watabe et al. 1986),
respectively. To date, both enzymes are still only incom-
pletely characterised and no sequence or structural informa-
tion is available.
Most known epoxide hydrolases belong to the large fam-
ily of / hydrolase fold enzymes and are found in nearly
every organism (van Loo et al. 2006). Yet, in bacteria also
diVerent strategies for epoxide hydrolysis evolved. Such
enzymes are generally specialised on a function in one spe-
ciWc pathway rather than accepting a broad spectrum of
substrates. The limonene epoxide hydrolase (LEH) from
Rhodococcus erythropolis (van der Werf et al. 1998), as
well as a homologous EH (TbEH1) from Mycobacterium
tuberculosis represent enzymes smaller than the general /
hydrolase fold EHs, and utilise a single step mechanism for
epoxide hydrolysis. A distinct class of EHs is represented
by the FosX epoxide hydrolases from microorganisms such
as Mesorhizobium loti and Listeria monocytogenes which
selectively hydrolyses the antibiotic Fosfomycin by a
mechanism including the direct addition of water (Fillgrove
et al. 2003; Rigsby et al. 2005).
This review focuses on an update of the / hydrolase
fold family of mammalian epoxide hydrolases and their
role in xenobiotic metabolism, but will also summarise the
functions of these enzymes which derive from hydrolysis of
endogenous lipid mediators.
Nomenclature of epoxide hydrolases
Several epoxide hydrolases and their corresponding genes
have been characterised in mammals. Historically, these
enzymes were named after the species of origin, the subcel-
lular localisation and/or their substrate speciWcity. Given
that the present gene nomenclature is not consistent but
most of the mammalian EHs belong to the / hydrolase
Fig. 1 The role of epoxide hydrolase in xenobiotic metabolism and
cell signalling. a Epoxides are in general chemically reactive com-
pounds, due to the electronegativity of the ring oxygen in combination
with a certain ring tension. b Reactive epoxides may be taken up by
the body as xenobiotic substrates or formed during metabolism, main-
ly by the action of cytochrome P450 dependant monooxygenases. On
the other hand, many epoxides without any genotoxic potential have
been identiWed as endogenous signalling molecules, which display
numerous functions within the organism. The turnover of epoxide to
the corresponding diols by epoxide hydrolases is most often consid-
ered a detoxifying reaction. Rather rare exceptions where (1) the
action of an EH leads to metabolic bioactivation, or (2) the diol reac-
tion product still has signalling function are outlined in the respective
chapters in the text
a
b
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fold family of enzymes, a more systematic nomenclature
based on evolutionary relation similar to the cytochrome
P450 monooxygenases (CYP) nomenclature seems appro-
priate. The two well investigated mammalian EHs have
been named EPHX1 (mEH) and EPHX2 (sEH) by the
HUGO gene nomenclature committee, therefore we suggest
that this nomenclature should also be used for new mem-
bers of the / hydrolase fold EH enzyme family (Table 1).
As mentioned earlier, we identiWed two new epoxide
hydrolase genes (presently termed ABHD7 and ABHD9
based on a predicted / hydrolase fold) with 45%
sequence identity in the mammalian genome (Fig. 2), at
least one of which acts as an epoxide hydrolase on lipid
derived epoxides (manuscript in preparation). Two structur-
ally very closely related EHs from Caenorhabditis elegans
have very recently been described (Harris et al. 2008) as
active epoxide hydrolases. Therefore we suggest terming
the two new mammalian enzymes EH3 and EH4 and pro-
pose changing their gene names into EPHX3 and EPHX4.
Because for the peg1/MEST gene product the evidence for
epoxide hydrolase activity has not been proven so far, and
for ChEH and Hepoxilin A3 hydrolase no sequence infor-
mation is available yet, we propose terming the next
sequence- and substrate-characterised / hydrolase fold
epoxide hydrolase EH5.
Gene evolution and structure of / hydrolase fold 
epoxide hydrolases
The / hydrolase fold family comprises of a broad variety
of enzymes with catalytic activities ranging from esterases
(acetylcholinesterase being the most prominent) to epoxide
hydrolases, haloalkane dehalogenases and lipases (Holmquist
2000). The sequence similarity of the Wrst cloned epoxide
hydrolase—mEH (Gonzalez and Kasper 1981)—and the
Wrst described bacterial haloalkane dehalogenase (Janssen
et al. 1989) is minimal but a classiWcation into the /
hydrolase fold family of enzymes based on structural simi-
larities (Arand et al. 1994; Lacourciere and Armstrong
1994; Beetham et al. 1995) was suggested after (1) cloning
of the related sEH (Beetham et al. 1993; Grant et al. 1993;
Knehr et al. 1993), and (2) determination of the crystal
structure of haloalkane dehalogenase (Franken et al. 1991).
The structural relationship of epoxide hydrolases has been
described in detail in a recent review (Arand et al. 2003a).
Since then approximately 240 epoxide hydrolase genes
have been described from plants, fungi, insects and bacteria
(Beetham et al. 1993, 1995; Smit 2004; van Loo et al.
2006). Another recent excellent review describes the
genome wide analysis for epoxide hydrolases and evolu-
tionary relationship of the identiWed enzymes with an aver-
age amino acid sequence identity of 14% into eight
phylogenetically related groups (van Loo et al. 2006).
The Wrst structure of an EH from Agrobacterium radiob-
acter (Nardini et al. 1999) with sequence similarity to
mammalian sEH revealed typical structural elements of /
hydrolase fold EHs. Common to all is a conserved fold con-
sisting of an arrangement of eight central -strands, Xanked
by several -helices. A variable lid domain that is inserted
between strand 6 and 7 covers this / hydrolase core fold
(Holmquist 2000). Both, core and lid domains constitute
the epoxide hydrolase substrate binding pocket at the inter-
action site. Similar in all family members is a catalytic triad
formed by the central fold consisting of an Asp-His-Asp/
Glu motif (catalytic nucleophile—water activating histi-
dine—acidic residue, forming a charge relay system with
Table 1 Nomenclature of mammalian / hydrolase fold epoxide
hydrolases
Peg1/MEST should only be termed EPHX5 when the MEST protein
has conWrmed epoxide hydrolase activity. We do not recommend
involving non-/ hydrolase fold EHs, e.g. Leukotriene A4 hydrolase
(LTA4H), or other mammalian EHs like Hepoxilin A3 hydrolase and
Cholesterol epoxide hydrolase (ChEH) in the respective nomenclature,
unless sequence information is available
EPHX Epoxide hydrolase xenobiotic, HYL hydrolase, ABHD /
hydrolase, Peg1/MEST paternally expressed gene 1/mesoderm speciWc
transcript
Gene description 
present
Recommended Protein description
recommended
EPHX1 (HYL1) EPHX1 Microsomal epoxide 
hydrolase, mEH
EPHX2 (HYL2) EPHX2 Soluble epoxide 
hydrolase, sEH
ABHD9 EPHX3 Epoxide hydrolase 3, EH3
ABHD7 EPHX4 Epoxide hydrolase 4, EH4
Peg1/MEST (EPHX5, possibly) MEST
Fig. 2 Phylogenetic tree of mammalian epoxide hydrolases. Protein
sequence comparison of human epoxide hydrolases sEH, mEH, EH3,
EH4 as well as MEST in their / hydrolase fold domains (displayed
in red). The percent sequence identity is indicated at the branches. The
lid domains are coloured in green. All proteins contain variable N-ter-
minal extension, such as the phosphatase domain (blue) in case of the
soluble epoxide hydrolase, membrane anchors (grey) or the N-terminal
meander of microsomal epoxide hydrolase (yellow)
45%
mEH (EPHX1)
sEH (EPHX2)
peg1/MEST
EH4 (EPHX4)
EH3 (EPHX3)30%
15%
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the histidine), located on top of certain loops (Fig. 3). In the
primary sequence the order of the catalytic triad is nucleo-
phile-acid-histidine (Arand et al. 1994). The lid domain
presents two tyrosine residues which position the epoxide
within the active site. These two tyrosines distinguish epox-
ide hydrolases from other members of the / hydrolase
fold family. The latter fold is ideally suited to a detoxifying
enzyme that needs to be able to turn over a large number of
structurally diverse epoxides (Arand et al. 2003a), because
the catalytic nucleophile is positioned at the top of a Xexi-
ble turn and therefore able to accept structurally diverse
epoxides. A negative charge which is formed on the car-
bonyl oxygen of the catalytic nucleophile (see mechanism
below) is stabilised further by a backbone amide of a
conserved sequence stretch HGXP (where X is usually aro-
matic) called oxyanion hole. Apart from these motifs, the
overall sequence variation is high which is typical for this
type of enzymes (a comparison of the EHs from A. radiob-
acter and A. niger shows little sequence similarity but the
backbones of their / hydrolase fold domains are nearly
perfectly superimposable). To date the structures of several
/ hydrolase fold epoxide hydrolases, in particular of
murine (Argiriadi et al. 1999) and human (Gomez et al.
2004) sEH, but also of plant (Mowbray et al. 2006), fungal
(Zou et al. 2000) and bacterial enzymes (Nardini et al.
1999) have been solved.
Fig. 3 Three dimensional struc-
ture and enzymatic mechanism 
of / hydrolase fold EHs. The 
structure model represents the 
Aspergillus niger epoxide 
hydrolase, a close relative of the 
mammalian mEH, prepared us-
ing the program PyMOL (v9.07; 
DeLano ScientiWc LLC, San 
Carlos, CA, USA) based on the 
coordinates from PDB data Wle 
1QO7. a Complete subunit with 
the / hydrolase fold displayed 
in red, the lid domain in green 
and the N-terminal meander in 
gold. b Stereo view of the mEH 
active site, showing the residues 
relevant for catalysis. c Two step 
catalytic mechanism of epoxide 
hydrolysis as described in detail 
in the text
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The N-terminal domain varies among mammalian
epoxide hydrolases (Arand et al. 2003a) (Fig. 2). While
the / hydrolase fold in mEH and most likely EH3 and 4
is preceded by a membrane anchor, the N-terminal
domain of mammalian sEH acts as a phosphatase and
structurally belongs to a distinct class of haloacid
dehalogenases (HAD). Structure and function of this
additional domain is detailed in the respective sEH chap-
ter below.
Catalytic mechanism of epoxide hydrolysis
Much work has been invested in elucidating the catalytic
mechanism of epoxide hydrolases (Arand et al. 1996;
Muller et al. 1997; Laughlin et al. 1998; Argiriadi et al.
1999; Armstrong and Cassidy 2000; Zou et al. 2000;
Arand et al. 2003c; Elfstrom and Widersten 2006) which
is well understood by now. The overall reaction catalyses
the addition of water to the oxirane ring leading to a vici-
nal diol as reaction product, including the formation of an
ester intermediate as outlined in Fig. 3c. As described
above the active site is composed of a catalytic triad build
from the active site residues aspartic acid (catalytic nucle-
ophile), histidine (general base) and aspartic or glutamic
acid (charge relay acid). The catalytic triad is supported in
catalysis by the two tyrosine residues coming from the lid.
The hydroxy groups of these tyrosines hydrogen bond to
the epoxide oxygen, once the substrate has entered the
active site, and thereby position and activate the epoxide
for the catalytic reaction. In the Wrst chemical reaction
step the catalytic nucleophile attacks the oxirane ring
(with certain stereo- and enantioselectivity depending on
the enzyme) at one of the two carbon atoms to form a
covalent intermediate (Lacourciere et al. 1993). In a sec-
ond step the enzyme substrate ester intermediate is then
hydrolysed by a water molecule, which is activated by
proton abstraction from the histidine of the catalytic triad.
The resulting positive charge is shielded by the acidic
amino acid residue, either a glutamic (in mammalian EHs)
or aspartic acid (in most other EHs) and the oxyanion hole
stabilises the intermediate state. The catalytic nucleophile
is located on a nucleophilic elbow, and can therefore
adapt to the position of the substrate epoxide with some
Xexibility. This setting represents the ideal active site for
broad substrate speciWcity.
Such a mechanism has some important implications in
the detoxiWcation capacity of epoxide hydrolases (Arand
et al. 2003c). The rate limiting step of the overall reaction is
the hydrolysis of the ester intermediate (Laughlin et al.
1998; Arand et al. 1999a) and release of a diol product.
However, in the Wrst reaction step—which represents sub-
strate consumption—the mEH is eYciently able to detoxify
a variety of substrates, although with low Vmax.1 The latter
fact is accomplished by the fortunate high expression level
of mEH in the liver and a generally low concentration of
epoxide substrates. Nonetheless, if the formation rate of a
reactive epoxide intermediate exceeds the elimination
capacity of the mEH, its steady state level is escaping the
control of the enzyme. This may represent the mechanistic
basis of a practical threshold for chemical carcinogenesis
by compounds that are detoxiWed by mEH (Oesch et al.
2000).
The catalytic addition of water to oxiranes by / hydro-
lase fold epoxide hydrolases as described above is not the
only possible mechanism to metabolise epoxides. To make
matters complete, three other mechanisms for epoxide
hydrolysis have evolved. Mammalian LTA4 hydrolase
(Haeggstrom et al. 2002) as well as the FosX epoxide
hydrolases from Mesorhizobium loti (Fillgrove et al. 2003;
Rigsby et al. 2005) are both metalloenzymes that activate
the oxirane by coordination with Zn2+ and Mn2+, respec-
tively. While FosX hydrolyses its substrate by direct addi-
tion of water, LTA4 introduces the water three double
bonds afar from the epoxide, resulting—as an exception—
in a non-vicinal diol. A one step mechanism of hydrolysis
is utilised by some bacterial enzymes—LEH from Rhodo-
coccus erythropolis and TbEH1 from Mycobacterium
tuberculosis (Arand et al. 2003b; Johansson et al. 2005)—
which form an active site containing the catalytic residues
Asp-Arg-Asp (Arand et al. 2003a). Compared to the broad
substrate spectrum of mEH, all latter enzymes show rather
narrow substrate selectivity.
Mammalian / hydrolase fold epoxide hydrolases
Microsomal epoxide hydrolase (EC 3.3.2.9)
Gene and protein structure
The human EPHX1 gene is located on the long arm of chro-
mosome 1 and approximately 20 kb in size, composed of
eight introns and nine exons, of which exons 2–9 are cod-
ing (Falany et al. 1987). In mammals, several alternative
non-coding exons 1 exist, that provide the possibility of
1 In an enzymatic reaction involving a covalent intermediate the
Michaelis constant Km resolves to Km = KD £ k2/(k1 + k2) (where k1
describes formation of the intermediate, whereas k2 describes the prod-
uct formation) and in the case of k2 being orders of magnitudes smaller
than k1 as mentioned above, k2 becomes negligible in the denominator,
and the ratio Km/KD equals the ratio k2/k1. Km is therefore orders of
magnitudes smaller then the dissociation constant, which is mimicking
a high aYnity of the enzyme for its substrate as detailed in Arand et al
(2003c) DetoxiWcation strategy of epoxide hydrolase—the basis for a
threshold in chemical carcinogenesis. EXCLI J 2:22–30.
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recruiting alternative promoters for mEH expression
(Gaedigk et al. 1997).
EPHX1 translates into a 455 amino acid polypeptide
containing an N-terminal membrane anchor (Friedberg
et al. 1994b). A crystal structure of human mEH is not
available, however, based on the X-ray structure of a
related enzyme from Aspergillus niger (which lacks the
N-terminal membrane anchor) a structural analysis of
mammalian mEH (Arand et al. 1999a; Zou et al. 2000) was
performed. The typical / hydrolase fold is covered by a
lid domain, but unique for mEH compared to other /
hydrolases is an N-terminal meander that clasps around
both core and lid domain (Fig. 3a). Because the Aspergillus
EH represents a dimer, it is intriguing to speculate that
human mEH may also exist in dimeric form. The mEH
active site was analysed by site directed mutagenesis of
mEH protein expressed in E. coli (Laughlin et al. 1998;
Tzeng et al. 1998) and S. cerevisiae (Arand et al. 1996),
which identiWed the catalytic triad as Asp226, Glu404 and
His431 and the two tyrosine are represented by residues
Tyr299 and 374 (Armstrong and Cassidy 2000). Micro-
somal EHs are the only epoxide hydrolases containing a
glutamate as acidic residue. Replacing Glu with Asp leads
to an mEH variant so far not found in the animal kingdom
with a 30-fold increase in the turnover rate (Arand et al.
1999b). This raises the question why evolution would
favour the apparently “ineYcient” enzyme variant. One
explanation might be that a strong enhancement of the
mEH turnover rate could have some undesired eVects on
endogenous EH substrates (e.g. signalling lipid epoxides)
with potential side eVects for the organism.
Organ and cellular distribution
Microsomal epoxide hydrolase is highly expressed in the
liver and other organs such as the lungs, kidneys, intestine,
brain, prostate, heart and testes (Coller et al. 2001).
Because mEH seems under a complex transcriptional con-
trol due to the utilisation of diVerent promoters, the mEH
expression level might vary in dependence on tissue and
cell type (Gaedigk et al. 1997). The human mEH expres-
sion is inducible by a number of compounds including phe-
nobarbitone and N-acetylaminoXuorene (Fig. 4c) (Astrom
et al. 1987; Hassett et al. 1989), eVects mediated by the
transcription factors Nrf2 (Kwak et al. 2001), GATA-4
(Zhu et al. 2004) and CAR (Merrell et al. 2008). The pro-
tein is attached to the cytosolic site of the endoplasmic
reticulum membrane with its N-terminal membrane anchor
Fig. 4 The substrate spectrum 
of microsomal epoxide 
hydrolase. a Substrates for 
mEH. b Inhibitors of 
microsomal epoxide hydrolase. 
c Inducers of microsomal 
epoxide hydrolase
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(Friedberg et al. 1994a; Holler et al. 1997), which corre-
lates to the membrane topology of CYPs. Some reports
though claim a localisation of mEH in the plasma mem-
brane, based on the enzymes possible function in bile acid
transport (Zou et al. 2000; von Dippe et al. 2003) which is,
however, a matter for debate (Honscha et al. 1995).
Physiological functions
The mEH classically plays a major role in xenobiotic
metabolism due to its exceptionally broad substrate selectiv-
ity and prominent expression in the liver and other metabol-
ising organs, ensuring widespread defence against potential
genotoxic epoxides. Due to the special mechanistic features
described above, the mEH is involved in the eYcient detox-
iWcation of many reactive epoxide intermediates (Armstrong
1987; Arand et al. 2003c) including metabolites of polycylic
aromatic hydrocarbons (Oesch 1973). Generally good sub-
strates for the mEH are lipophilic substituted epoxides of
cis-conWguration such as cis-stilbene oxide. Examples for
mEH substrates are epoxides derived from anticonvulsive
drugs (carbamazepine-10,11-epoxide) (Bellucci et al. 1987),
toxic and procarcinogenic compounds such as styrene-7,8-
oxide (Oesch 1974), epoxide derivatives of butadiene (Kra-
use et al. 1997), benzene (Snyder et al. 1993), naphthalene,
anthracene and other polycyclic aromatic hydrocarbons
(Bentley et al. 1976; van Bladeren et al. 1985; Shimada
2006) (Fig. 4a). The breakdown of such potential genotoxic
epoxide to less harmful metabolites is an eYcient process in
the protection of macromolecules from the electrophilic
attack of reactive intermediates.
The eYcient detoxiWcation of styrene oxide shows the
detoxiWcation capacity of human mEH (Oesch et al. 2000).
Styrene-7,8-oxide, which is the major genotoxic metabolite
of the industrial chemical styrene formed by CYPs in the
human liver (Sumner and Fennell 1994), is eYciently
metabolised by mEH to its less toxic metabolite phenyl gly-
col. However, already a low exogenous exposure to styrene
oxide (but not styrene) correlates with protein/DNA adduct
biomarkers for styrene oxide exposure (Rappaport et al.
1996). This is best explained by the assumption, that
endogenously formed styrene oxide is eYciently hydroly-
sed immediately after generation without leaving the liver,
while styrene oxide of exogenous origin Wrst has to reach
this organ via the circulation. This hypothesis is compatible
with the results from toxicokinetic models regarding sty-
rene and styrene metabolite exposure in rats, mice and
humans (Csanady et al. 2003). Furthermore, lung Wbro-
blasts engineered to express human mEH at the same level
as the human liver are well protected against the genotoxic
eVects of styrene-7,8-oxide after extended exposure, in
contrast to the corresponding parental cells that lack human
mEH (Herrero et al. 1997).
Under some circumstances the mEH is involved in the
toxiWcation of its substrates, with potentially fatal outcome.
Such a dual role of mEH is highlighted by its important role
in both detoxiWcation and bioactivation of the polycyclic aro-
matic hydrocarbon benzo[a]pyrene (Shou et al. 1996). While
the enzyme can detoxify many CYP derived epoxides, in
particular bay region dihydrodiol epoxides of PAHs are no
substrates for mEH, which consequently display a highly
genotoxic potential (Friedberg et al. 1994a). As displayed in
Fig. 5 the enzyme catalyses the regioselective addition of
water to the 8-position of (7R,8S)-benzo[a]pyrene-7,8-epox-
ide. The resulting dihydrodiol is still a good substrate for the
oxidation at the 9,10-position to result in the ultimate cancer-
ogen (7R,8S,9S,10R)-benzo[a]pyrene-7,8,9,10-tetrahydro-
7,8-diol-9,10-epoxide, which is not a substrate for mEH
anymore (Holder et al. 1974). A contentious issue still is as
to whether mEH is protective or toxifying in the case of
PAHs. Analysis in mEH knock out models may produce
valuable answers, but it should be kept in mind that the out-
come of results may heavily depend on the chosen experi-
mental model. Reduced carcinogenicity of 7,12-dimethyl
benz[a]anthracene (DMBA) in mEH knockout versus con-
trol animals was shown in a skin tumourigenicity model
(Miyata et al. 1999), and reduced immunosupression of
DMBA was reported after systemic application in KO versus
control animals (Gao et al. 2007). With another model sub-
strate, such as benzo[a]pyrene, the ratio of formation and
elimination of genotoxic metabolites may be diVerent and it
is not predictable whether systemic toxicity will be higher or
lower in mEH knockout mice compared to control litter-
mates. mEH null mice have further been used to show a pro-
tective eVect of the enzyme against butadiene (WickliVe
et al. 2007), but genotoxicity and haematotoxicity of benzene
are again enhanced in these animals (Recio et al. 2005).
Another controversial question is the detoxiWcation capacity
of mEH for aXatoxin-B1-8,9-exo-epoxide, the short lived but
highly genotoxic metabolite of aXatoxin B1 produced by
Aspergillus Xavus (a fungus particularly contaminating corn
and peanuts). A high incidence of hepatocellular carcinomas
is observed in regions with high incidences of hepatitis in
combination with high aXatoxin exposure (McGlynn et al.
1995). The turnover rate for aXatoxin-B1-8,9-exo-epoxide
with human mEH is rather slow in vitro compared to the
spontaneous hydrolysis (Guengerich et al. 1998), but due to
the afore mentioned mechanism the protective capacity of
mEH may be underestimated. Several studies have con-
nected the susceptibility towards aXatoxin induced hepato-
carcinogenesis to polymorphisms in the mEH gene
(McGlynn et al. 1995; Wild et al. 2000; McGlynn et al.
2003; Dash et al. 2007). Furthermore, mEH has been
reported to provide some protection against the mutagenicity
of aXatoxin-B1-8,9-exo-epoxide in recombinant S. cerevisiae
(Kelly et al. 2002).
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On the other hand, endogenous functions of mEH have
long been widely overlooked. Endogenous substrates for
mEH are certain steroids like estroxide (Fandrich et al.
1995) or androstene oxide, suggesting a role in develop-
ment. Latest reports also connect mEH to neurodegenera-
tive disorders such as Alzheimers and Parkinsons disease
(Liu et al. 2006, 2008). Despite the fact that the sEH is the
main enzyme to metabolise numerous endogenous fatty
acid derived epoxides (see below), mEH also accepts fatty
acid derived epoxides such as epoxystearic acid with high
enantioselectivity (Zeldin et al. 1996), EETs (Oliw et al.
1982) or an epoxide of anandamide (Snider et al. 2007),
although generally to a much lesser extent than sEH. There-
fore, a role of mEH in signalling cascades cannot be
excluded, particularly in the case of a high mEH expression
in certain organs or cell types.
A number of mEH inhibitors have been developed to
investigate mechanistic aspects of epoxide hydrolysis or an
involvement of the enzyme in pathophysiology. 1,1,1,-Tri-
chloropropene-2,3-oxide was found to be an inhibitor of
rodent and human mEH (Papadopoulos et al. 1985) and
cyclopropyl oxiranes are competitive reversible inhibitors
for mEH (Prestwich et al. 1985) (Fig. 4c). Also the anticon-
vulsant valpromide was identiWed as a mEH inhibitor and
recently other substituted fatty acid amides (elaidamide)
were developed as metabolically stable mEH inhibitors of
much higher aYnity (Morisseau et al. 2001, 2008).
Polymorphisms
Two prominent genetic polymorphisms (Tyr113His and
His139Arg) have been identiWed in the coding region of
mEH (Omiecinski et al. 2000), both displaying ethnic
diVerences. The protein variants resulting from the diVerent
haplotypes have been reported to display diVerent half lives
(Hassett et al. 1994, 1997), so that these genetic variants
may have impact on mEH activity in vivo. mEH polymor-
phisms may lead to diVerences in bioactivation of procar-
cinogens, resulting in altered susceptibilities to cancers of
various tissues (Tranah et al. 2005; Lin et al. 2007; Mittal
and Srivastava 2007). Studies associating mEH polymor-
phism with lung cancer have obtained apparently contradic-
tory results (Habalova et al. 2004). However, two meta
analysis associated the His113/His139 haplotype (predicted
slow activity) with a signiWcantly decreased risk of lung
cancer (Lee et al. 2002; Kiyohara et al. 2006). Other studies
associate the His113/His139 variant with a protective eVect
regarding chronic obstructive pulmonary disease (Brogger
et al. 2006), as well as a decreased risk of pregnancy
induced hypertension (preeclampsia) (Zusterzeel et al.
2001), but on the other hand an increased susceptibility to
development of liver cancer after exposure to aXatoxin-B1
(Hengstler et al. 1998; McGlynn et al. 2003) was demon-
strated. The His113/His139 variant further has been reported
to be more frequent in COPD and lung emphysema patients
Fig. 5 Metabolism of ben-
zo[a]pyrene. The representation 
shows the metabolic activation 
of benzo[a]pyrene to ben-
zo[a]pyrene-7,8-dihydrodiol-
8,9-epoxide, the ultimate carcin-
ogenic metabolite, which is no 
substrate for mEH anymore. The 
other pathways describe meta-
bolic reactions by phase II 
enzymes leading to 
detoxiWcation of reactive 
reaction intermediates
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as compared to healthy controls (Smith and Harrison 1997).
Moreover, several other polymorphisms have been identi-
Wed in the 5-Xanking region of the mEH promoter region
(Raaka et al. 1998).
Soluble epoxide hydrolase (EC 3.3.2.10, EC 3.1.3.76)
Gene and protein structure
The human EPHX2 gene is located on chromosome 8,
approximately 54 kb in size, and composed of 19 exons and
18 introns (Sandberg and Meijer 1996). Two alternative
ovary speciWc transcripts EPHX2B and C have recently
been described, that both substitute the Wrst two exons of
the known sEH sequence (Hennebold et al. 2005; Shkolnik
et al. 2007). This results in a sEH protein which lacks
essential catalytic components of its N-terminal phospha-
tase domain (see below), while leaving the epoxide hydro-
lase domain intact. These alternative transcripts are
particularly interesting as the sEH knockout line (Sinal
et al. 2000) was constructed by disruption of the Wrst intron,
whereas in a second established knock out line (Luria et al.
2007) the exact disruption site is not published. Thus, the
knock out may be incomplete in both cases, with respect to
the epoxide hydrolase activity of the enzyme.
Mammalian sEH has a primary structure of 554 amino
acids (Beetham et al. 1993; Grant et al. 1993; Knehr et al.
1993). One sEH monomer is constituted of two separate
catalytic domains—a phosphatase in the N-terminus and
the epoxide hydrolase in the C-terminus—separated by a
proline rich linker (Fig. 6a). Mammalian sEH is a homodi-
meric enzyme showing a domain swapped architecture,
where the N-terminal domain of one subunit interacts with
the C-terminal domain of the other. Both domains are clas-
siWed within large and separate superfamilies of hydrolases
based on structural similarities. The structures of murine
(Argiriadi et al. 1999) and human (Gomez et al. 2004) sEH
have been solved giving interesting insights into the mecha-
nism of the enzyme. The C-terminal domain (325 amino
acids) of each subunit functions as a / hydrolase fold
epoxide hydrolase as described earlier. The catalytic triad
of rodent sEH is composed of the active site residues
Asp333, Asp495 and His523 (Pinot et al. 1995; Arand et al.
1996) and the two tyrosines Tyr382 and Tyr465 (Argiriadi
et al. 1999).
The smaller N-terminal domain instead displays a
recently discovered phosphatase activity (Cronin et al.
2003; Newman et al. 2003). This phosphatase domain
belongs to a distinct family of HADs, comprising a number
of phosphatases, dehalogenases and other hydrolases
(Koonin and Tatusov 1994; Beetham et al. 1995). Albeit an
overall low sequence similarity, all enzymes of the HAD
superfamily possess a structurally conserved rossmannoid
fold (core domain), containing four loops that form the cat-
alytic scaVold (Fig. 6a). Loop 1 contains the catalytic Asp
nucleophile followed by a second aspartic acid (Wang et al.
2002; Allen and Dunaway-Mariano 2004). Loops 2 and 3
orientate the phosphate substrate with residues Ser/Thr and
Lys/Arg, whereas loop 4 contains the Mg2+ binding pocket
formed by two aspartic acids (Baker et al. 1998; Morais
et al. 2000; Wang et al. 2001). Additionally, the HAD
enzymes are divided into three subfamilies I–III due to the
presence and location of an additional cap domain. Class I
HADs such as the sEH phosphatase contain an insertion
between loop 1 and 2 of the core domain (Lahiri et al. 2004,
2006). This cap domain is implicated in solvent protection
of the active site as well as substrate selectivity (Selengut
2001). Based on structural similarities with other members
of the HAD family and site directed mutagenesis we identi-
Wed the composition of the active site as Asp9, Asp11,
Thr123, Asn124, Lys160, Asp184, Asp185 and Asn189.
We recently investigated the catalytic mechanism of
dephosphorylation, using kinetic evaluation of active site
mutants and LC–MS/MS analysis of the phosphorylated
enzyme intermediate. In the Wrst step in the dephosphoryla-
tion reaction, the phosphate residue is transferred from the
substrate to Asp9 which acts as the catalytic nucleophile
(Fig. 6b, c). In a second step the phosphoenzyme intermedi-
ate is hydrolysed via nucleophilic attack of an activated
water molecule (Cronin et al. 2008).
Cellular distribution
The sEH is expressed in almost every organ such as liver,
lungs, kidneys, heart, brain and ovary (Enayetallah et al.
2004; Sura et al. 2008). The enzyme is mainly localised in
the cell cytosol, but in some cell types sEH shows a dual
localisation, both cytosolic and peroxisomal. This is due to
an imperfect C-terminal peroxisomal targeting sequence
(PTS-1) (Arand et al. 1991; Mullen et al. 1999) and in
dependence of protein expression level and quaternary
structure (Enayetallah et al. 2006a; Luo et al. 2008).
In rodents, sEH expression is inducible by peroxisome
proliferators (PPs, a number of structurally diverse com-
pounds including hypolipidemic drugs such as Wbrates and
phthalates) (Fig. 7c), an eVect mediated by the transcription
factor peroxisome proliferator activated receptor (PPAR)
(Oesch et al. 1986; Lundgren et al. 1987; Johansson et al.
1995), which suggests a possible role of sEH in PP induced
liver cancerogenesis. A PPAR mediated induction of sEH
in humans has not yet been detected. Recently, an AP1
mediated regulation of sEH by Angiotensin-II has been
shown (Ai et al. 2007), and further Monti et al. (2008) iden-
tiWed an sEH genetic variant associated with heart failure in
rats, which is characterised by the existence of a new AP1-
binding site in the promoter region.
306 Arch Toxicol (2009) 83:297–318
123
Physiological functions
Most established sEH functions are currently assigned to
the epoxide hydrolase activity. In xenobiotic metabolism
the sEH complements the mEH spectrum of substrates for
an eYcient turnover, in that it hydrolyses trans-substituted
slender epoxides and shows complementary substrate spec-
iWcity to mEH (Morisseau and Hammock 2005), including
potentially harmful epoxides (Arand et al. 2003a). Typical
substrates are trans-stilbene oxide, and in particular fatty
Fig. 6 Three dimensional structure of soluble epoxide hydrolase and
catalytic mechanism of the sEH phosphatase. a Structure model of one
subunit of the homodimeric soluble epoxide hydrolase, consistent of
an N-terminal phosphatase (Core domain represented in green and lid
domain in gold) and the C-terminal epoxide hydrolase domain (/
hydrolase fold displayed in red and lid domain in blue). b Stereo view
of the sEH phosphatase active site, with the catalytic amino acids high-
lighted. The structural model was prepared using the program PyMOL
(v9.07; DeLano ScientiWc LLC, San Carlos, CA, USA) based on the
coordinates from the PDB data Wle 1CQZ. c Two step mechanism of
dephosphorylation as described in detail in the text
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acid derived substrates (Fig. 7a). Fatty acids such as cis-
9,10-epoxystearic acid have been identiWed as excellent
substrates for mammalian sEH (Zeldin et al. 1993;
Summerer et al. 2002), but in contrast to soybean sEH or
mammalian mEH with little enantioselectivity or enantio-
convergence (Summerer et al. 2002).
In contrast to a classical role in detoxiWcation processes,
the major physiological role of sEH certainly is the metabo-
lism of fatty acid derived epoxides to the corresponding
diols. The organism utilises a large number of endogenous
epoxides—mainly derived from arachidonic acid (EETs)
and linoleic acid (leukotoxin)—as important signalling
molecules and physiological regulators. One of the Wrst
reports of physiological relevance was the sEH catalysed
turnover of leukotoxin to the actual toxic metabolite
leukotoxin diol, causing multiple organ failure and adult
respiratory distress syndrome after severe body burns
(Moghaddam et al. 1996). Human sEH is the primary
enzyme that metabolises such endogenous epoxides (Mog-
haddam et al. 1996; Morisseau and Hammock 2005; New-
man et al. 2005), although other mammalian epoxide
hydrolases may play a physiological role under certain con-
ditions.
Due to its important role in the lipid metabolism of
EETs, the sEH has recently evolved as a target for the treat-
ment of hypertension (Fang et al. 2001; Imig 2005; Newman
et al. 2005), inXammatory diseases (Liu et al. 2005;
Schmelzer et al. 2005; Inceoglu et al. 2006), and a novel
treatment of pain, diabetes and stroke (Ohtoshi et al. 2005;
Schmelzer et al. 2006; Spector and Norris 2007; Zhang
Fig. 7 The substrate spectrum 
of soluble epoxide hydrolase. 
a Substrates of soluble epoxide 
hydrolase. b Inhibitors of 
soluble epoxide hydrolase. 
c Inducers of soluble epoxide 
hydrolase. d Substrates of the 
sEH phosphatase
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et al. 2007). The formation of cis-EETs is catalysed by
various CYPs and sEH hydrolyses all EET regioisomers
with the order of preference being 14,15-EET > 11,12-
EET > 8,9-EET > 5,6-EET. The breakdown of EETs by
sEH is in general believed to be a deactivation process.
EETs were identiWed as endothelium derived hyperpolari-
sation factor, causing prostacyclin and NO independant
vasodilation in vascular beds (Fisslthaler et al. 1999),
which created massive interest in these lipid derived epox-
ides. EETs (released from the endothelium) act on large
conductance calcium activated K+ channels (BKCa) on vas-
cular smooth muscle cells leading to hyperpolarisation and
vasodilation (Hu and Kim 1993; Li and Campbell 1997) by
a mechanism including Gs activation (Li and Campbell
1997). To complicate matters, the diVerent EET regioisom-
ers may have opposing eVects dependant on the cell type
and experimental set up, and EET eVects might be stereose-
lective (Imig et al. 1996; Falck et al. 2003; Pomposiello
et al. 2003; Newman et al. 2005). Despite contradictory
reports on the inXuence of sEH gene disruption on basal
blood pressure (possibly due to compensation by the vaso-
constrictor 20-HETE) in sEH null mice (Sinal et al. 2000;
Luria et al. 2007), several experimental hypertensive mod-
els have indeed shown a role of EETs in blood pressure reg-
ulation and end organ protection, using speciWc sEH
inhibitors (Imig et al. 2002; Zhao et al. 2004; Fang 2006; Li
et al. 2008; Zhang et al. 2008a). Very recently the sEH has
been shown to be a susceptibility factor for heart failure in a
rat model (Monti et al. 2008). Evidence is accumulating
that EETs also display anti-inXammatory properties, by a
mechanism based on disruption of the proinXammatory
Nfb signalling pathway. sEH inhibitors attenuated
tobacco smoke induced lung inXammation in rats (Smith
et al. 2005), and sEH KO mice also showed a survival
advantage following acute systemic inXammation induced
by lipopolysaccharides, eVects that might at least in part be
mediated by PPAR (Liu et al. 2005; Inceoglu et al. 2006;
Schmelzer et al. 2006). The latter studies also pointed to an
antinociceptive eVect of EETs, as administration of sEH
inhibitors decrease LPS-induced thermal hyperalgesia and
mechanical allodynia in a systemic model of inXammatory
pain (Inceoglu et al. 2006), an eVect enhanced by coadmin-
istration of sEH inhibitors and common non-steroidal anti-
inXammatory drugs (Schmelzer et al. 2006). Very recently
14,15-EET was shown to mediate its antinociceptive eVect
via the - and -opioid receptor pathway (Terashvili et al.
2008). Because EETs play important roles in the brain—
including regulation of cerebral blood Xow and protection
from ischemic brain injury—sEH has emerged as a poten-
tial pharmacological target for the treatment of stroke
(Zhang et al. 2007, 2008b; Gschwendtner et al. 2008).
Finally, several studies point to an eVect of EETs on cell
proliferation (Potente et al. 2003), migration (Sun et al.
2002) and angiogenesis (Michaelis et al. 2005), actions
which seem mediated through several signalling pathways
including p38 MAPK, PI3K Akt or PKA and in dependence
of the species, the type of endothelium and/or the EET reg-
ioisomer (Spector and Norris 2007).
Due to the various described endogenous functions of
EETs, inhibitors for sEH (sEHI) have been developed over
the past decade, aiming in particular at new therapeutics for
the treatment of hypertension. sEHIs comprise of several
chemical classes such as chalcone oxide derivatives
(Morisseau et al. 1998), trans-3-phenylglycidols (Dietze
et al. 1991, 1993), as well as urea and carbamate-based
inhibitors (Morisseau et al. 2002, 2006; Kim et al. 2004,
2007) (Fig. 7c).
In contrast, the physiological role of the recently discov-
ered phosphatase activity of sEH is much less clear, but it
further highlights the role of this enzyme in regulatory pro-
cesses. The sEH phosphatase so far accepts the generic sub-
strate 4-NPP, some lipid phosphates (Newman et al. 2003;
Tran et al. 2005), as well as isoprenoid phosphates (Enay-
etallah et al. 2006b; Enayetallah and Grant 2006). Of these
threo-9,10-phosphonooxy-hydroxy-octadecanoic acid as
well as the monophosphates of farnesol and geraniol are
among the best substrates (Fig. 7d). Because isoprenoid
phosphates are intermediate metabolites at the branching
point of cholesterol biosynthesis as well as precursors for
protein prenylation, the sEH phosphatase is possibly con-
nected to cholesterol biosynthesis, protein prenylation and
metabolism of certain lipid phosphates. Due to the dual
localisation of sEH in cell cytosol and peroxisomes, the
physiological target of the sEH phosphatase activity might
be organelle speciWc. Recently two ovary speciWc alterna-
tive transcripts—EPHX2B and C—of the sEH have been
identiWed (Hennebold et al. 2005; Shkolnik et al. 2007)
both of which are shortened at the N-terminus leading to an
inactive phosphatase domain. EPHX2C is found in the
ovary at the highest level of expression occurring during
the luteal phase of a stimulated oestrous cycle, suggesting a
role of the sEH phosphatase in hormonal regulation.
EVorts are being made to develop speciWc sEH phospha-
tase inhibitors (Tran et al. 2005; Enayetallah et al. 2006a),
but due to the large collection of endogenous phosphatases
this seems to be a challenging task.
Polymorphisms
A number of non-synonymous nucleotide polymorphisms
(Lys55Arg, Arg103Cys, Cys154Tyr, Arg287Gln, Val422Ala
and Glu470Gly, insertion Arg402ArgArg) have been iden-
tiWed for human sEH (Sandberg et al. 2000; Saito et al.
2001; Przybyla-Zawislak et al. 2003) that aVect the protein
coding sequence as well as enzymatic activity. Of these,
sEH variant Lys55Arg, which has increased epoxide hydrolase
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activity, is associated with coronary artery disease, espe-
cially in Caucasian, but not African American cigarette
smokers (Lee et al. 2006). The most signiWcant polymor-
phism however is represented by sEH variant Arg287Gln
which seems to be associated with a number of diseases.
The Arg287Gln mutation results in sEH protein with
reduced stability and reduced epoxide hydrolase activity
(Przybyla-Zawislak et al. 2003), as well as decreased abil-
ity of homodimer formation (Srivastava et al. 2004) and
therefore facilitated peroxisomal import (Luo et al. 2008).
The reported results on phosphatase activity are inconsis-
tent, increased phosphatase activity (Enayetallah and Grant
2006) as well as decreased phosphatase activity of the
Arg287Gln mutant as compared to the WT enzymes using
isoprenoid phosphates and/or generic substrate (Srivastava
et al. 2004) are described. The allelic frequencies for the
Arg287Gln allele are 5% for Europeans, 20% for Asians
and 8% for Africans. The Arg287Gln allele was associated
with increased risks for coronary artery calciWcation in
African Americans, but not caucasians (Fornage et al.
2004; Burdon et al. 2008), insulin resistance in diabetes
type II patients (Ohtoshi et al. 2005), ischemic stroke
(Koerner et al. 2007), as well as hypercholesterolemia (Sato
et al. 2004) in carriers of a LDL-receptor mutation.
EH 3 and 4
The genes EPHX3 and 4 are closely related, the correspond-
ing gene products EH3 and EH4 are polypeptides of 360 and
362 amino acids in length, respectively. EH 3 and 4 show a
sequence identity of 45%, with higher sequence similarity to
sEH than mEH (Fig. 2). Both proteins contain a predicted N-
terminal membrane anchor. No report of an endogenous sub-
strate for EH3 and 4 is available yet, but at least EH3 repre-
sents a functional epoxide hydrolase. Substrate spectrum as
well as expression pattern of both enzymes are currently
being assessed in our group (manuscript in preparation).
The Wrst hints to cellular distribution of EH3 and 4 stem
from EST and microarray database analysis, according to
which expression of EH 3 is generally low but found in
lung, tongue and skin. A recent study of the human epider-
mal transcriptome demonstrated a high expression of EH3
in human granular keratinocytes (Toulza et al. 2007), and a
human/mouse conserved coexpression analysis to predict
human disease genes suggests EPHX3 as candidate gene
for ichthyosis (Ala et al. 2008). Moreover, EPHX3 gains
some attention as methylation marker for cancer prognosis.
In many cancers tumour suppressor genes are inactivated
by methylation silencing of their promoter regions. CpG
islands in the promoter region of EPHX3 are methylated in
melanoma cell lines compared to cultured human epidermal
melanocytes (Furuta et al. 2006), as well as in primary gas-
tric cancers and multiple gastric cancer cell lines (Yamashita
et al. 2006). EPHX3 was further identiWed as candidate
marker for prostate cancer prognosis by showing increased
methylation levels in patients with early PSA recurrence
compared to non-recurrent patients (Cottrell et al. 2007).
These results indicate a transcriptional silencing of the
EPHX3 gene in some cancer events.
In contrast, an expression of EH4 is reported mainly in
the brain and eyes. Studies in our group (manuscript in
preparation) and expression analysis of rat brain (Stansberg
et al. 2007) conWrm these Wndings.
Taken together, the expression pattern suggests a role for
both enzymes in the regulation of endogenous functions rather
than a role in xenobiotic metabolism. Future investigation will
show the exact physiological function of both enzymes.
MEST
The paternally expressed gene 1/mesoderm speciWc tran-
script (peg1/MEST) is an imprinted gene that is widely
expressed in mammalian tissue (Kobayashi et al. 1997). As
an imprinted gene, peg1 shows a promoter methylation pat-
tern that reXects a strict parent-of-origin-speciWc diVeren-
tial methylation (Lefebvre et al. 1997). Expression of peg1/
MEST stays imprinted in adult mice and humans and is
high in the nervous system, but an occasional loss of
imprinting occurs in cases of invasive breast cancer (Peder-
sen et al. 1999) and lung adenocarcinoma (Nakanishi et al.
2004). The 335 amino acid polypeptide has a predicted N-
terminal membrane anchor. An epoxide hydrolase activity
of peg1/MEST still needs to be conWrmed, however the
protein shows signiWcant sequence similarity to / fold
epoxide hydrolases (Kaneko-Ishino et al. 1995). MEST
contains one conserved, probably epoxide-coordinating
tyrosine in the primary sequence and two related epoxide
hydrolases from M. tuberculosis do indeed show weak
epoxide hydrolase activity (personal observations).
A physiological function of MEST has not yet been
established, but the fact that MEST is an imprinted gene
suggests an important role in development. Targeted disrup-
tion of peg1/MEST leads to growth retardation and behav-
ioural eVects (Lefebvre et al. 1997). Very recently MEST
has been associated with fat mass expansion in response to a
high fat diet, due to an up to 50-fold upregulation of mRNA
and protein levels in adipose tissue (Nikonova et al. 2008),
which further suggest a role of MEST in lipid metabolism.
Other mammalian epoxide hydrolases
Hepoxilin epoxide hydrolase (EC 3.3.2.7)
Hepoxilin epoxide hydrolase was partly puriWed from rat
liver cytosol (Pace-Asciak and Lee 1989) and discriminated
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from sEH due to its size of 53 kDa and substrate selectivity
for hepoxilin A3, while showing only marginal activity
towards leukotriene or styrene oxide. Because Hepoxilin
EH is not cloned to date the question remains whether this
enzyme belongs to the family of / hydrolase fold EHs.
A function in xenobiotic metabolism is—despite an expres-
sion in the liver—unlikely, due to the rather speciWc sub-
strate spectrum.
Hepoxilins (hydroxyepoxy eicosanoids) are widely dis-
tributed in mammals (Newman et al. 2005; Nigam et al.
2007). The trans-epoxides hepoxilin A3 and B3 are derived
from the action of 12-lipoxygenase on arachidonic acid and
may be degraded by the action of an EH (to the correspond-
ing trihydroxy metabolite trioxilin) or conjugation with glu-
tathione (Laneuville et al. 1991). Hepoxilins formed in rat
pancreatic islets enhance the glucose dependant secretion
of insulin (Pace-Asciak and Martin 1984). Hepoxilins facil-
itate calcium transport (Derewlany et al. 1984), and they
are further formed in the brain with synaptic neuromodula-
tory actions on hippocampal neurons by hyperpolarisation
and enhancement of the inhibitory postsynaptic potential
(Pace-Asciak et al. 1990, 1995). Hepoxilin signalling is
most likely receptor mediated, an assumption based on the
identiWcation of a hepoxilin binding protein in human neu-
trophils (Reynaud et al. 1999). Hepoxilin A3 seems to be a
key regulator of neutrophil migration in response to an
inXammation response (Mrsny et al. 2004). Due to the
occurrence of increased hepoxilins and trioxilin levels in
psoriatic lesions the lipids are thought to act proinXamma-
tory in the skin (Anton et al. 1998). Moreover, mutations in
the hepoxilin generating epidermal lipoxygenase pathway
are associated with a congenital form of ichthyosis. This
suggests an involvement of these lipid mediators in epider-
mal diVerentiation and skin barrier function (Brash et al.
2007; Epp et al. 2007; Yu et al. 2007).
Nonetheless, hepoxilin A3 and B3 are excellent sub-
strates for mammalian sEH (manuscript in preparation).
The enzyme is further expressed in hepoxilin generating
tissue, which strongly suggests a physiological function of
sEH in hepoxilin metabolism. The regulation of these sig-
nalling molecules might occur by both enzymes depending
on cell type/tissue or regulatory state.
Cholesterol epoxide hydrolase (EC 3.3.2.11)
The existence of an epoxide hydrolase speciWc for choles-
terol-5,6-epoxide was already described 1974 (Aringer
and Eneroth 1974; Chan and Black 1976; Oesch et al.
1984). ChEH is widely distributed in mammals (Astrom
et al. 1986), but little is known about the enzyme and no
gene sequence is available. An induction of ChEH has been
reported in rodents exposed to the PPAR agonist cloWbrate
(Finley and Hammock 1988), like as for sEH. Although
also present in microsomal cell fractions, ChEH activity is
distinct from mEH (Oesch et al. 1984). Moreover, several
lines of evidence suggest that ChEH does not represent a
,-hydrolase fold EH. Size exclusion analysis of the native
enzyme partly puriWed from mouse liver suggested ChEH
to be smaller than a typical , hydrolase fold epoxide
hydrolase (Watabe et al. 1986). In contrast to mEH and
sEH the enzyme could not be labelled covalently with 14C-
cholesterol-5,6-epoxide. These results led to the specula-
tion that ChEH might hydrolyse its substrate via a diVerent
mechanism and represents the Wrst mammalian EH member
similar to the recently described bacterial LEH (EC.
3.3.2.8) from Rhodococcus erythropolis (Barbirato et al.
1998). The LEH hydrolyses its substrate in a single step
mechanism and further shares structural similarity to an
epoxide hydrolase from Mycobacterium tuberculosum
(TbEH1). Strikingly, this TbEH1 is the only other enzyme
able to facilitate such a bulky substrate like cholesterol-5,6-
epoxide (Arand et al. 2003a, b; Johansson et al. 2005).
An oxidation of cholesterol proceeds as part of the lipid
peroxidation process in membranes (Astrom et al. 1986),
and ChEH functions in conversion of 5,6-epoxicholes-
tane-3-ol and 5,6-epoxicholestane-3-ol to cholestane-
3,5,6-triol (Watabe et al. 1981). Some toxicological
interest arose from cholesterol epoxide which was reported
to act as a weak direct acting mutagen (Sevanian and Peter-
son 1984, 1986). Cholesterol epoxide was further the sus-
pected dermatocarcinogen in hairless mice irradiated by
UV. The mutagenicity of cholesterol epoxide in V79 Chi-
nese hamster lung Wbroblasts (Black and Douglas 1972;
Reddy and Wynder 1977; Sevanian and Peterson 1984)
suggests that the ChEH might play a role in protecting cells
from these steroid toxicants, however, the cholesterol epox-
ides are quiet stable and the corresponding cholestantriols
are themselves cytotoxic (Wilson et al. 1997; Vejux et al.
2007). Further, cholesterol epoxides are implicated in apop-
tosis (Ryan et al. 2004), as well as vascular function and
coronary artery disease (Rimner et al. 2005) because they
are found upregulated in arteriosclerotic lesions. Only a
complete characterisation of ChEH can help to fully under-
stand the physiological role of this enzyme.
Leukotriene A4 hydrolase (EC 3.3.2.6)
As an atypical epoxide hydrolase Leukotriene A4 hydrolase
will only be brieXy addressed, and we refer to some recent
excellent reviews (Chen et al. 2004; Haeggstrom 2004;
Newman et al. 2005; Haeggstrom et al. 2007). The enzyme
has been cloned (Funk et al. 1987), puriWed from rat and
human erythrocytes and neutrophiles (Radmark et al. 1984;
Evans et al. 1985; McGee and Fitzpatrick 1985), and the
crystal structure has been solved (Tsuge et al. 1994; Thun-
nissen et al. 2001). LTA4H is not related to mEH, sEH or
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other /-hydrolases, instead the bifunctional metallopro-
tein LTA4H possesses an epoxide hydrolase as well as a
aminopeptidase activity (Haeggstrom et al. 1990; Minami
et al. 1990).
The aminopeptidase activity is of presently unknown
biological function, although limited peptide substrates
have been described (GriYn et al. 1992). LTA4H hydro-
lyses leukotriene A4 which is generated via the 5-lipoxyge-
nase pathway from arachidonic acid—not like sEH to the
vicinal diol—but to LTB4, a non-vicinal 5,12-diol (McGee
and Fitzpatrick 1985). LTB4 is a potent chemotactic agent
for neutrophiles, eosinophiles, monocytes and T-Cells,
which all play key roles in immune response. Therefore
LTA4H is strongly linked to the pathophysiology of arterio-
sclerosis, myocardial infarction and stroke (Haeggstrom
2004). Because LTA4H generally functions as a proinXam-
matory enzyme, LTA4H has as of late attracted attention as
a target for cancer prevention. LTA4H inhibitors prevented
DMBA induced oral carcinogenesis in hamsters (Sun et al.
2006) and inhibited proliferation as well as induced apopto-
sis in pancreatic adenocarcinomas (Zhou et al. 2007).
Outlook
Albeit the important role of epoxide hydrolases—mEH in
particular—in xenobiotic metabolisms it is now evident
that epoxide hydrolases have vital roles in endogenous reg-
ulatory processes. This seems also the case for the newly
identiWed potential epoxide hydrolases. Only a throughout
characterisation of these enzymes including an evaluation
of the substrate spectrum and identiWcation of cellular EH
substrate receptors will clear their physiological function.
The potential of mammalian epoxide hydrolases as drug
targets is highlighted by the growing interest in the devel-
opment of eVective epoxide hydrolase inhibitors.
References
Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy
JY, Zhu Y (2007) Angiotensin II up-regulates soluble epoxide
hydrolase in vascular endothelium in vitro and in vivo. Proc Natl
Acad Sci USA 104:9018–9023. doi:10.1073/pnas.0703229104
Ala U, Piro RM, Grassi E, Damasco C, Silengo L, Oti M, Provero P,
Di Cunto F (2008) Prediction of human disease genes by human-
mouse conserved coexpression analysis. PLoS Comput Biol
4:e1000043. doi:10.1371/journal.pcbi.1000043
Allen KN, Dunaway-Mariano D (2004) Phosphoryl group transfer:
evolution of a catalytic scaVold. Trends Biochem Sci 29:495–503.
doi:10.1016/j.tibs.2004.07.008
Anton R, Puig L, Esgleyes T, de Moragas JM, Vila L (1998) Occur-
rence of hepoxilins and trioxilins in psoriatic lesions. J Invest Der-
matol 110:303–310. doi:10.1046/j.1523-1747.1998.00159.x
Arand M, Knehr M, Thomas H, Zeller HD, Oesch F (1991) An
impaired peroxisomal targeting sequence leading to an unusual
bicompartmental distribution of cytosolic epoxide hydrolase.
FEBS Lett 294:19–22. doi:10.1016/0014-5793(91)81333-4
Arand M, Grant DF, Beetham JK, Friedberg T, Oesch F, Hammock
BD (1994) Sequence similarity of mammalian epoxide hydro-
lases to the bacterial haloalkane dehalogenase and other related
proteins. Implication for the potential catalytic mechanism of
enzymatic epoxide hydrolysis. FEBS Lett 338:251–256.
doi:10.1016/0014-5793(94)80278-5
Arand M, Wagner H, Oesch F (1996) Asp333, Asp495, and His523
form the catalytic triad of rat soluble epoxide hydrolase. J Biol
Chem 271:4223–4229. doi:10.1074/jbc.271.8.4223
Arand M, Hemmer H, Durk H, Baratti J, Archelas A, Furstoss R,
Oesch F (1999a) Cloning and molecular characterization of a sol-
uble epoxide hydrolase from Aspergillus niger that is related to
mammalian microsomal epoxide hydrolase. Biochem J 344(Pt
1):273–280. doi:10.1042/0264-6021:3440273
Arand M, Muller F, Mecky A, Hinz W, Urban P, Pompon D, Kellner
R, Oesch F (1999b) Catalytic triad of microsomal epoxide hydro-
lase: replacement of Glu404 with Asp leads to a strongly in-
creased turnover rate. Biochem J 337(Pt 1):37–43. doi:10.1042/
0264-6021:3370037
Arand M, Cronin A, Oesch F, Mowbray SL, Jones TA (2003a) The
telltale structures of epoxide hydrolases. Drug Metab Rev
35:365–383. doi:10.1081/DMR-120026498
Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ,
de Bont JA, Jones TA, Mowbray SL (2003b) Structure of Rhodo-
coccus erythropolis limonene-1, 2-epoxide hydrolase reveals a
novel active site. EMBO J 22:2583–2592. doi:10.1093/emboj/
cdg275
Arand M, Herrero Plana ME, Hengstler JG, Lohmann M, Cronin A,
Oesch F (2003c) DetoxiWcation strategy of epoxide hydrolase—
the basis for a threshold in chemical carcinogenesis. EXCLI J
2:22–30
Argiriadi MA, Morisseau C, Hammock BD, Christianson DW (1999)
DetoxiWcation of environmental mutagens and carcinogens:
structure, mechanism, and evolution of liver epoxide hydrolase.
Proc Natl Acad Sci USA 96:10637–10642. doi:10.1073/
pnas.96.19.10637
Aringer L, Eneroth P (1974) Formation and metabolism in vitro of 5,
6-epoxides of cholesterol and beta-sitosterol. J Lipid Res 15:389–
398
Armstrong RN (1987) Enzyme-catalyzed detoxication reactions:
mechanisms and stereochemistry. CRC Crit Rev Biochem 22:39–
88. doi:10.3109/10409238709082547
Armstrong RN, Cassidy CS (2000) New structural and chemical
insight into the catalytic mechanism of epoxide hydrolases. Drug
Metab Rev 32:327–338. doi:10.1081/DMR-100102337
Astrom A, Eriksson M, Eriksson LC, Birberg W, Pilotti A, DePierre
JW (1986) Subcellular and organ distribution of cholesterol epox-
ide hydrolase in the rat. Biochim Biophys Acta 882:359–366
Astrom A, Maner S, DePierre JW (1987) Induction of liver
microsomal epoxide hydrolase, UDP-glucuronyl transferase and
cytosolic glutathione transferase in diVerent rodent species by
2-acetylaminoXuorene or 3-methylcholanthrene. Xenobiotica
17:155–163
Baker AS, Ciocci MJ, Metcalf WW, Kim J, Babbitt PC, Wanner BL,
Martin BM, Dunaway-Mariano D (1998) Insights into the mech-
anism of catalysis by the P-C bond-cleaving enzyme phosphono-
acetaldehyde hydrolase derived from gene sequence analysis and
mutagenesis. Biochemistry 37:9305–9315. doi:10.1021/
bi972677d
Barbirato F, Verdoes JC, de Bont JA, van der Werf MJ (1998) The
Rhodococcus erythropolis DCL14 limonene-1, 2-epoxide hydro-
lase gene encodes an enzyme belonging to a novel class of epoxide
hydrolases. FEBS Lett 438:293–296. doi:10.1016/S0014-5793
(98)01322-2
312 Arch Toxicol (2009) 83:297–318
123
Beetham JK, Tian T, Hammock BD (1993) cDNA cloning and expres-
sion of a soluble epoxide hydrolase from human liver. Arch Bio-
chem Biophys 305:197–201. doi:10.1006/abbi.1993.1411
Beetham JK, Grant D, Arand M, Garbarino J, Kiyosue T, Pinot F,
Oesch F, Belknap WR, Shinozaki K, Hammock BD (1995) Gene
evolution of epoxide hydrolases and recommended nomenclature.
DNA Cell Biol 14:61–71
Bellucci G, Berti G, Chiappe C, Lippi A, Marioni F (1987) The metab-
olism of carbamazepine in humans: steric course of the enzymatic
hydrolysis of the 10, 11-epoxide. J Med Chem 30:768–773.
doi:10.1021/jm00388a004
Bentley P, Schmassmann H, Sims P, Oesch F (1976) Epoxides derived
from various polycyclic hydrocarbons as substrates of homoge-
neous and microsome-bound epoxide hydratase. A general assay
and kinetic properties. Eur J Biochem 69:97–103. doi:10.1111/
j.1432-1033.1976.tb10862.x
Black HS, Douglas DR (1972) A model system for the evaluation of
the role of cholesterol-oxide in ultraviolet carcinogenesis. Cancer
Res 32:2630–2632
Brash AR, Yu Z, Boeglin WE, Schneider C (2007) The hepoxilin con-
nection in the epidermis. FEBS J 274:3494–3502. doi:10.1111/
j.1742-4658.2007.05909.x
Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P (2006) Genetic
association between COPD and polymorphisms in TNF, ADRB2
and EPHX1. Eur Respir J 27:682–688. doi:10.1183/09031936.
06.00057005
Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman
BI, Herrington D, Bowden DW (2008) Genetic analysis of the
soluble epoxide hydrolase gene, EPHX2, in subclinical cardio-
vascular disease in the Diabetes Heart Study. Diab Vasc Dis Res
5:128–134. doi:10.3132/dvdr.2008.021
Chan JT, Black HS (1976) Distribution of cholesterol-5alpha, 6alpha-
epoxide formation and its metabolism in mouse skin. J Invest Der-
matol 66:112–116. doi:10.1111/1523-1747.ep12481460
Chen X, Wang S, Wu N, Yang CS (2004) Leukotriene A4 hydrolase as
a target for cancer prevention and therapy. Curr Cancer Drug Tar-
gets 4:267–283. doi:10.2174/1568009043333041
Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M, Kroemer HK,
Murdter TE (2001) Distribution of microsomal epoxide hydrolase
in humans: an immunohistochemical study in normal tissues, and
benign and malignant tumours. Histochem J 33:329–336.
doi:10.1023/A:1012414806166
Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M,
Hartmann A, Stamey T, HaeXiger C, Weiss G (2007) Discovery
and validation of 3 novel DNA methylation markers of prostate
cancer prognosis. J Urol 177:1753–1758. doi:10.1016/j.ju-
ro.2007.01.010
Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B,
Oesch F, Arand M (2003) The N-terminal domain of mammalian
soluble epoxide hydrolase is a phosphatase. Proc Natl Acad Sci
USA 100:1552–1557. doi:10.1073/pnas.0437829100
Cronin A, Homburg S, Durk H, Richter I, Adamska M, Frere F,
Arand M (2008) Insights into the catalytic mechanism of human
sEH phosphatase by site-directed mutagenesis and LC-MS/MS
analysis. J Mol Biol 383:627–640. doi:10.1016/j.jmb.2008.
08.049
Csanady GA, Kessler W, HoVmann HD, Filser JG (2003) A toxicoki-
netic model for styrene and its metabolite styrene-7, 8-oxide in
mouse, rat and human with special emphasis on the lung. Toxicol
Lett 138:75–102. doi:10.1016/S0378-4274(02)00409-5
Dash B, Afriyie-Gyawu E, Huebner HJ, Porter W, Wang JS, Jolly PE,
Phillips TD (2007) Determinants of the variability of aXatoxin-
albumin adduct levels in Ghanaians. J Toxicol Environ Health A
70:58–66. doi:10.1080/15287390600748880
Derewlany LO, Pace-Asciak CR, Radde IC (1984) Hepoxilin A,
hydroxyepoxide metabolite of arachidonic acid, stimulates
transport of 45Ca across the guinea pig visceral yolk sac. Can J
Physiol Pharmacol 62:1466–1469
Dietze EC, Kuwano E, Casas J, Hammock BD (1991) Inhibition of
cytosolic epoxide hydrolase by trans-3-phenylglycidols. Biochem
Pharmacol 42:1163–1175. doi:10.1016/0006-2952(91)90250-9
Dietze EC, Stephens J, Magdalou J, Bender DM, Moyer M, Fowler B,
Hammock BD (1993) Inhibition of human and murine cytosolic
epoxide hydrolase by group-selective reagents. Comp Biochem
Physiol B 104:299–308. doi:10.1016/0305-0491(93)90372-C
Elfstrom LT, Widersten M (2006) Implications for an ionized alkyl-en-
zyme intermediate during StEH1-catalyzed trans-stilbene oxide
hydrolysis. Biochemistry 45:205–212. doi:10.1021/bi051893g
Enayetallah AE, French RA, Thibodeau MS, Grant DF (2004) Distri-
bution of soluble epoxide hydrolase and of cytochrome P450 2C8,
2C9, and 2J2 in human tissues. J Histochem Cytochem 52:447–
454
Enayetallah AE, Grant DF (2006) EVects of human soluble epoxide
hydrolase polymorphisms on isoprenoid phosphate hydrolysis.
Biochem Biophys Res Commun 341:254–260. doi:10.1016/
j.bbrc.2005.12.180
Enayetallah AE, French RA, Barber M, Grant DF (2006a) Cell-speciWc
subcellular localization of soluble epoxide hydrolase in human
tissues. J Histochem Cytochem 54:329–335. doi:10.1369/jhc.
5A6808.2005
Enayetallah AE, French RA, Grant DF (2006b) Distribution of soluble
epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human
malignant neoplasms. J Mol Histol 37:133–141. doi:10.1007/
s10735-006-9050-9
Epp N, Furstenberger G, Muller K, de Juanes S, Leitges M, Hausser I,
Thieme F, Liebisch G, Schmitz G, Krieg P (2007) 12R-lipoxyge-
nase deWciency disrupts epidermal barrier function. J Cell Biol
177:173–182. doi:10.1083/jcb.200612116
Evans JF, Dupuis P, Ford-Hutchinson AW (1985) PuriWcation and
characterisation of leukotriene A4 hydrolase from rat neutrophils.
Biochim Biophys Acta 840:43–50
Falany CN, McQuiddy P, Kasper CB (1987) Structure and organiza-
tion of the microsomal xenobiotic epoxide hydrolase gene. J Biol
Chem 262:5924–5930
Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB,
Deeter C, Sharma KK, Gauthier KM, Campbell WB (2003) Com-
parison of vasodilatory properties of 14, 15-EET analogs: struc-
tural requirements for dilation. Am J Physiol Heart Circ Physiol
284:H337–H349
Fandrich F, Degiuli B, Vogel-Bindel U, Arand M, Oesch F (1995)
Induction of rat liver microsomal epoxide hydrolase by its endog-
enous substrate 16 alpha, 17 alpha-epoxyestra-1, 3, 5-trien-3-ol.
Xenobiotica 25:239–244
Fang X (2006) Soluble epoxide hydrolase: a novel target for the
treatment of hypertension. Recent Pat Cardiovasc Drug Discov
1:67–72
Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau
C, Thompson DA, Hammock BD, Spector AA (2001) Pathways
of epoxyeicosatrienoic acid metabolism in endothelial cells.
Implications for the vascular eVects of soluble epoxide hydrolase
inhibition. J Biol Chem 276:14867–14874. doi:10.1074/jbc.
M011761200
Fillgrove KL, Pakhomova S, Newcomer ME, Armstrong RN (2003)
Mechanistic diversity of fosfomycin resistance in pathogenic
microorganisms. J Am Chem Soc 125:15730–15731. doi:10.1021/
ja039307z
Finley BL, Hammock BD (1988) Increased cholesterol epoxide hydro-
lase activity in cloWbrate-fed animals. Biochem Pharmacol
37:3169–3175. doi:10.1016/0006-2952(88)90316-4
Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse
R (1999) Cytochrome P450 2C is an EDHF synthase in coronary
arteries. Nature 401:493–497. doi:10.1038/46816
Arch Toxicol (2009) 83:297–318 313
123
Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND
(2004) Polymorphism of the soluble epoxide hydrolase is associ-
ated with coronary artery calciWcation in African-American sub-
jects: The Coronary Artery Risk Development in Young Adults
(CARDIA) study. Circulation 109:335–339. doi:10.1161/01.CIR.
0000109487.46725.02
Franken SM, Rozeboom HJ, Kalk KH, Dijkstra BW (1991) Crystal
structure of haloalkane dehalogenase: an enzyme to detoxify
halogenated alkanes. EMBO J 10:1297–1302
Friedberg T, Becker R, Oesch F, Glatt H (1994a) Studies on the impor-
tance of microsomal epoxide hydrolase in the detoxiWcation of
arene oxides using the heterologous expression of the enzyme in
mammalian cells. Carcinogenesis 15:171–175. doi:10.1093/
carcin/15.2.171
Friedberg T, Lollmann B, Becker R, Holler R, Oesch F (1994b) The
microsomal epoxide hydrolase has a single membrane signal
anchor sequence which is dispensable for the catalytic activity of
this protein. Biochem J 303(Pt 3):967–972
Funk CD, Radmark O, Fu JY, Matsumoto T, Jornvall H, Shimizu T,
Samuelsson B (1987) Molecular cloning and amino acid sequence
of leukotriene A4 hydrolase. Proc Natl Acad Sci USA 84:6677–
6681. doi:10.1073/pnas.84.19.6677
Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima
T (2006) Silencing of Peroxiredoxin 2 and aberrant methylation
of 33 CpG islands in putative promoter regions in human malig-
nant melanomas. Cancer Res 66:6080–6086. doi:10.1158/0008-
5472.CAN-06-0157
Gaedigk A, Leeder JS, Grant DM (1997) Tissue-speciWc expression
and alternative splicing of human microsomal epoxide hydrolase.
DNA Cell Biol 16:1257–1266
Gao J, Lauer FT, Mitchell LA, Burchiel SW (2007) Microsomal exp-
oxide hydrolase is required for 7, 12-dimethylbenz[a]anthracene
(DMBA)-induced immunotoxicity in mice. Toxicol Sci 98:137–
144. doi:10.1093/toxsci/kfm089
Gomez GA, Morisseau C, Hammock BD, Christianson DW (2004)
Structure of human epoxide hydrolase reveals mechanistic infer-
ences on bifunctional catalysis in epoxide and phosphate ester
hydrolysis. Biochemistry 43:4716–4723. doi:10.1021/bi036189j
Gonzalez FJ, Kasper CB (1981) Cloning of epoxide hydratase comple-
mentary DNA. J Biol Chem 256:4697–4700
Grant DF, Storms DH, Hammock BD (1993) Molecular cloning and
expression of murine liver soluble epoxide hydrolase. J Biol
Chem 268:17628–17633
GriYn KJ, Gierse J, Krivi G, Fitzpatrick FA (1992) Opioid peptides
are substrates for the bifunctional enzyme LTA4 hydrolase/ami-
nopeptidase. Prostaglandins 44:251–257. doi:10.1016/0090-
6980(92)90018-O
Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B,
Wichmann HE, Meitinger T, Dichgans M (2008) Genetic varia-
tion in soluble epoxide hydrolase (EPHX2) is associated with an
increased risk of ischemic stroke in white Europeans. Stroke
39:1593–1596. doi:10.1161/STROKEAHA.107.502179
Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H,
Langouet S (1998) Activation and detoxication of aXatoxin B1.
Mutat Res 402:121–128. doi:10.1016/S0027-5107(97)00289-3
Habalova V, Salagovic J, Kalina I, Stubna J (2004) Combined analysis
of polymorphisms in glutathione S-transferase M1 and micro-
somal epoxide hydrolase in lung cancer patients. Neoplasma
51:352–357
Haeggstrom JZ (2004) Leukotriene A4 hydrolase/aminopeptidase, the
gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol
Chem 279:50639–50642. doi:10.1074/jbc.R400027200
Haeggstrom JZ, Wetterholm A, Vallee BL, Samuelsson B (1990)
Leukotriene A4 hydrolase: an epoxide hydrolase with peptidase
activity. Biochem Biophys Res Commun 173:431–437.
doi:10.1016/ S0006-291X(05)81076-9
Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunnissen MM
(2002) Leukotriene A4 hydrolase. Prostaglandins Other Lipid
Mediat 68–69:495–510. doi:10.1016/S0090-6980(02)00051-5
Haeggstrom JZ, Tholander F, Wetterholm A (2007) Structure and cat-
alytic mechanisms of leukotriene A4 hydrolase. Prostaglandins
Other Lipid Mediat 83:198–202. doi:10.1016/j.prostaglandins.
2007.01.006
Harris TR, Aronov PA, Jones PD, Tanaka H, Arand M, Hammock BD
(2008) IdentiWcation of two epoxide hydrolases in Caenorhabdi-
tis elegans that metabolize mammalian lipid signaling molecules.
Arch Biochem Biophys
Hassett C, Turnblom SM, DeAngeles A, Omiecinski CJ (1989) Rabbit
microsomal epoxide hydrolase: isolation and characterization of
the xenobiotic metabolizing enzyme cDNA. Arch Biochem Bio-
phys 271:380–389. doi:10.1016/0003-9861(89)90287-7
Hassett C, Aicher L, Sidhu JS, Omiecinski CJ (1994) Human micro-
somal epoxide hydrolase: genetic polymorphism and functional
expression in vitro of amino acid variants. Hum Mol Genet
3:421–428. doi:10.1093/hmg/3.3.421
Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ (1997) Hu-
man hepatic microsomal epoxide hydrolase: comparative analysis
of polymorphic expression. Arch Biochem Biophys 337:275–
283. doi:10.1006/abbi.1996.9794
Hengstler JG, Arand M, Herrero ME, Oesch F (1998) Polymorphisms
of N-acetyltransferases, glutathione S-transferases, microsomal
epoxide hydrolase and sulfotransferases: inXuence on cancer sus-
ceptibility. Recent Results Cancer Res 154:47–85
Hennebold JD, Mah K, Perez W, Vance JE, StouVer RL, Morisseau C,
Hammock BD, Adashi EY (2005) IdentiWcation and characteriza-
tion of an ovary-selective isoform of epoxide hydrolase. Biol
Reprod 72:968–975. doi:10.1095/biolreprod.104.035899
Herrero ME, Arand M, Hengstler JG, Oesch F (1997) Recombinant
expression of human microsomal epoxide hydrolase protects V79
Chinese hamster cells from styrene oxide—but not from ethylene
oxide-induced DNA strand breaks. Environ Mol Mutagen
30:429–439. doi:10.1002/(SICI)1098-2280(1997)30:4<429::
AID-EM8>3.0.CO;2-D
Holder G, Yagi H, Dansette P, Jerina DM, Levin W, Lu AY, Conney
AH (1974) EVects of inducers and epoxide hydrase on the metab-
olism of benzo[a]pyrene by liver microsomes and a reconstituted
system: analysis by high pressure liquid chromatography. Proc
Natl Acad Sci USA 71:4356–4360. doi:10.1073/pnas.71.11.4356
Holler R, Arand M, Mecky A, Oesch F, Friedberg T (1997) The mem-
brane anchor of microsomal epoxide hydrolase from human, rat,
and rabbit displays an unexpected membrane topology. Biochem
Biophys Res Commun 236:754–759. doi:10.1006/bbrc.1997.7044
Holmquist M (2000) Alpha/beta-hydrolase fold enzymes: structures,
functions and mechanisms. Curr Protein Pept Sci 1:209–235.
doi:10.2174/1389203003381405
Honscha W, Platte HD, Oesch F, Friedberg T (1995) Relationship
between the microsomal epoxide hydrolase and the hepatocellular
transport of bile acids and xenobiotics. Biochem J 311(Pt 3):975–
979
Hu S, Kim HS (1993) Activation of K+ channel in vascular smooth
muscles by cytochrome P450 metabolites of arachidonic acid. Eur
J Pharmacol 230:215–221. doi:10.1016/0014-2999(93)90805-R
Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as
therapeutic targets for renal diseases. Am J Physiol Renal Physiol
289:F496–F503. doi:10.1152/ajprenal.00350.2004
Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR (1996) Actions
of epoxygenase metabolites on the preglomerular vasculature.
J Am Soc Nephrol 7:2364–2370
Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD (2002)
Soluble epoxide hydrolase inhibition lowers arterial blood pres-
sure in angiotensin II hypertension. Hypertension 39:690–694.
doi:10.1161/hy0202.103788
314 Arch Toxicol (2009) 83:297–318
123
Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD
(2006) Inhibition of soluble epoxide hydrolase reduces
LPS-induced thermal hyperalgesia and mechanical allodynia in
a rat model of inXammatory pain. Life Sci 79:2311–2319.
doi:10.1016/j.lfs.2006.07.031
Janssen DB, Pries F, van der Ploeg J, Kazemier B, Terpstra P, Witholt
B (1989) Cloning of 1, 2-dichloroethane degradation genes of
Xanthobacter autotrophicus GJ10 and expression and sequencing
of the dhlA gene. J Bacteriol 171:6791–6799
Johansson C, Stark A, Sandberg M, Ek B, Rask L, Meijer J (1995)
Tissue speciWc basal expression of soluble murine epoxide hydro-
lase and eVects of cloWbrate on the mRNA levels in extrahepatic
tissues and liver. Arch Toxicol 70:61–63. doi:10.1007/s0020400
50250
Johansson P, Unge T, Cronin A, Arand M, Bergfors T, Jones TA,
Mowbray SL (2005) Structure of an atypical epoxide hydrolase
from Mycobacterium tuberculosis gives insights into its function.
J Mol Biol 351:1048–1056. doi:10.1016/j.jmb.2005.06.055
Kaneko-Ishino T, Kuroiwa Y, Miyoshi N, Kohda T, Suzuki R, Yokoy-
ama M, Viville S, Barton SC, Ishino F, Surani MA (1995) Peg1/
Mest imprinted gene on chromosome 6 identiWed by cDNA
subtraction hybridization. Nat Genet 11:52–59. doi:10.1038/
ng0995-52
Kelly EJ, Erickson KE, Sengstag C, Eaton DL (2002) Expression of
human microsomal epoxide hydrolase in Saccharomyces
cerevisiae reveals a functional role in aXatoxin B1 detoxiWcation.
Toxicol Sci 65:35–42. doi:10.1093/toxsci/65.1.35
Kim IH, Morisseau C, Watanabe T, Hammock BD (2004) Design, syn-
thesis, and biological activity of 1, 3-disubstituted ureas as potent
inhibitors of the soluble epoxide hydrolase of increased water sol-
ubility. J Med Chem 47:2110–2122. doi:10.1021/jm030514j
Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Moris-
seau C, BlanchWeld J, Toth I, Hammock BD (2007) Design of bio-
available derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic
acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg
Med Chem 15:312–323. doi:10.1016/j.bmc.2006.09.057
Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y (2006) EPHX1
polymorphisms and the risk of lung cancer: a HuGE review. Epi-
demiology 17:89–99. doi:10.1097/01.ede.0000187627.70026.23
Knehr M, Thomas H, Arand M, Gebel T, Zeller HD, Oesch F (1993)
Isolation and characterization of a cDNA encoding rat liver cyto-
solic epoxide hydrolase and its functional expression in Esche-
richia coli. J Biol Chem 268:17623–17627
Kobayashi S, Kohda T, Miyoshi N, Kuroiwa Y, Aisaka K, Tsutsumi O,
Kaneko-Ishino T, Ishino F (1997) Human PEG1/MEST, an
imprinted gene on chromosome 7. Hum Mol Genet 6:781–786.
doi:10.1093/hmg/6.5.781
Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF,
Alkayed NJ (2007) Polymorphisms in the human soluble epoxide
hydrolase gene EPHX2 linked to neuronal survival after ischemic
injury. J Neurosci 27:4642–4649. doi:10.1523/JNEUROSCI.00
56-07.2007
Koonin EV, Tatusov RL (1994) Computer analysis of bacterial
haloacid dehalogenases deWnes a large superfamily of hydrolases
with diverse speciWcity. Application of an iterative approach to
database search. J Mol Biol 244:125–132. doi:10.1006/jmbi.
1994.1711
Krause RJ, Sharer JE, Elfarra AA (1997) Epoxide hydrolase-depen-
dent metabolism of butadiene monoxide to 3-butene-1, 2-diol in
mouse, rat, and human liver. Drug Metab Dispos 25:1013–1015
Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW (2001) Role
of transcription factor Nrf2 in the induction of hepatic phase 2 and
antioxidative enzymes in vivo by the cancer chemoprotective
agent, 3H–1, 2-dimethiole-3-thione. Mol Med 7:135–145
Lacourciere GM, Armstrong RN (1994) Microsomal and soluble epox-
ide hydrolases are members of the same family of C-X bond
hydrolase enzymes. Chem Res Toxicol 7:121–124. doi:10.1021/
tx00038a001
Lacourciere GM, Vakharia VN, Tan CP, Morris DI, Edwards GH,
Moos M, Armstrong RN (1993) Interaction of hepatic micro-
somal epoxide hydrolase derived from a recombinant baculovirus
expression system with an azarene oxide and an aziridine sub-
strate analogue. Biochemistry 32:2610–2616. doi:10.1021/
bi00061a019
Lahiri SD, Zhang G, Dai J, Dunaway-Mariano D, Allen KN (2004)
Analysis of the substrate speciWcity loop of the HAD superfamily
cap domain. Biochemistry 43:2812–2820. doi:10.1021/bi0356810
Lahiri SD, Zhang G, Dunaway-Mariano D, Allen KN (2006) Diversi-
Wcation of function in the haloacid dehalogenase enzyme
superfamily: the role of the cap domain in hydrolytic phosphorus-
carbon bond cleavage. Bioorg Chem 34:394–409. doi:10.1016/
j.bioorg.2006.09.007
Laneuville O, Corey EJ, Couture R, Pace-Asciak CR (1991) Hepoxilin
A3 (HxA3) is formed by the rat aorta and is metabolized into
HxA3-C, a glutathione conjugate. Biochim Biophys Acta
1084:60–68
Laughlin LT, Tzeng HF, Lin S, Armstrong RN (1998) Mechanism of
microsomal epoxide hydrolase. Semifunctional site-speciWc mu-
tants aVecting the alkylation half-reaction. Biochemistry
37:2897–2904. doi:10.1021/bi972737f
Lee WJ, Brennan P, BoVetta P, London SJ, Benhamou S, Rannug A,
To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L,
Taioli E (2002) Microsomal epoxide hydrolase polymorphisms
and lung cancer risk: a quantitative review. Biomarkers 7:230–
241. doi:10.1080/13547500210121882
Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW,
Hammock BD, Couper DJ, Heiss G, Zeldin DC (2006) Genetic
variation in soluble epoxide hydrolase (EPHX2) and risk of coro-
nary heart disease: The Atherosclerosis Risk in Communities
(ARIC) study. Hum Mol Genet 15:1640–1649. doi:10.1093/hmg/
ddl085
Lefebvre L, Viville S, Barton SC, Ishino F, Surani MA (1997) Geno-
mic structure and parent-of-origin-speciWc methylation of Peg1.
Hum Mol Genet 6:1907–1915. doi:10.1093/hmg/6.11.1907
Li PL, Campbell WB (1997) Epoxyeicosatrienoic acids activate K+
channels in coronary smooth muscle through a guanine nucleotide
binding protein. Circ Res 80:877–884
Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT (2008)
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-
sensitive hypertension. Front Biosci 13:3480–3487. doi:10.2741/
2942
Lin TS, Huang HH, Fan YH, Chiou SH, Chow KC (2007) Genetic
polymorphism and gene expression of microsomal epoxide
hydrolase in non-small cell lung cancer. Oncol Rep 17:565–572
Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA,
Gill S, Morisseau C, Hammock BD, Shyy JY (2005) The antiin-
Xammatory eVect of laminar Xow: the role of PPARgamma, ep-
oxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl
Acad Sci USA 102:16747–16752. doi:10.1073/pnas.0508081102
Liu M, Sun A, Shin EJ, Liu X, Kim SG, Runyons CR, Markesbery W,
Kim HC, Bing G (2006) Expression of microsomal epoxide
hydrolase is elevated in Alzheimer’s hippocampus and induced
by exogenous beta-amyloid and trimethyl-tin. Eur J Neurosci
23:2027–2034. doi:10.1111/j.1460-9568.2006.04724.x
Liu M, Hunter R, Nguyen XV, Kim HC, Bing G (2008) Microsomal
epoxide hydrolase deletion enhances tyrosine hydroxylase phos-
phorylation in mice after MPTP treatment. J Neurosci Res
86:2792–2801
Lundgren B, Meijer J, DePierre JW (1987) Induction of cytosolic and
microsomal epoxide hydrolases and proliferation of peroxisomes
and mitochondria in mouse liver after dietary exposure to p-chlo-
rophenoxyacetic acid, 2, 4-dichlorophenoxyacetic acid and 2, 4,
Arch Toxicol (2009) 83:297–318 315
123
5-trichlorophenoxyacetic acid. Biochem Pharmacol 36:815–821.
doi:10.1016/0006-2952(87)90169-9
Luo B, Norris C, Bolstad ES, Knecht DA, Grant DF (2008) Protein
quaternary structure and expression levels contribute to peroxi-
somal-targeting-sequence-1-mediated peroxisomal import of
human soluble epoxide hydrolase. J Mol Biol 380:31–41.
doi:10.1016/j.jmb.2008.04.064
Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang
H, Gill R, Morisseau C, Newman JW, Hammock BD (2007)
Compensatory mechanism for homeostatic blood pressure regula-
tion in Ephx2 gene-disrupted mice. J Biol Chem 282:2891–2898.
doi:10.1074/jbc.M608057200
McGee J, Fitzpatrick F (1985) Enzymatic hydration of leukotriene A4.
PuriWcation and characterization of a novel epoxide hydrolase
from human erythrocytes. J Biol Chem 260:12832–12837
McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou
T, Wild CP, Xia XL, BaVoe-Bonnie A, Ofori-Adjei D et al (1995)
Susceptibility to hepatocellular carcinoma is associated with
genetic variation in the enzymatic detoxiWcation of aXatoxin B1.
Proc Natl Acad Sci USA 92:2384–2387. doi:10.1073/pnas.92.6.
2384
McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA,
Shen FM, Evans AA, London WT, Buetow KH (2003) Suscepti-
bility to aXatoxin B1-related primary hepatocellular carcinoma in
mice and humans. Cancer Res 63:4594–4601
Merrell MD, Augustine LM, Slitt AL, Cherrington NJ (2008) Induc-
tion of drug metabolism enzymes and transporters by oltipraz in
rats. J Biochem Mol Toxicol 22:128–135. doi:10.1002/jbt.20225
Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I,
Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are
implicated in hypoxia-induced endothelial cell migration and
angiogenesis. J Cell Sci 118:5489–5498. doi:10.1242/jcs.02674
Minami M, Ohishi N, Mutoh H, Izumi T, Bito H, Wada H, Seyama Y,
Toh H, Shimizu T (1990) Leukotriene A4 hydrolase is a zinc-con-
taining aminopeptidase. Biochem Biophys Res Commun
173:620–626. doi:10.1016/S0006-291X(05)80080-4
Mittal RD, Srivastava DL (2007) Cytochrome P4501A1 and micro-
somal epoxide hydrolase gene polymorphisms: gene–environ-
ment interaction and risk of prostate cancer. DNA Cell Biol
26:791–798. doi:10.1089/dna.2007.0630
Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salgu-
ero P, Kimura S, Gonzalez FJ (1999) Targeted disruption of the
microsomal epoxide hydrolase gene. Microsomal epoxide hydro-
lase is required for the carcinogenic activity of 7, 12-dimethyl-
benz[a]anthracene. J Biol Chem 274:23963–23968. doi:10.1074/
jbc.274.34.23963
Moghaddam M, Motoba K, Borhan B, Pinot F, Hammock BD (1996)
Novel metabolic pathways for linoleic and arachidonic acid
metabolism. Biochim Biophys Acta 1290:327–339
Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A,
Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz
H, Patone G, Saar K, Vingron M, Weldon SM, Lindpaintner K,
Hammock BD, Rohde K, Dietz R, Cook SA, Schunck WH, Luft
FC, Hubner N (2008) Soluble epoxide hydrolase is a susceptibil-
ity factor for heart failure in a rat model of human disease. Nat
Genet 40:529–537. doi:10.1038/ng.129
Morais MC, Zhang W, Baker AS, Zhang G, Dunaway-Mariano D,
Allen KN (2000) The crystal structure of bacillus cereus phospho-
noacetaldehyde hydrolase: insight into catalysis of phosphorus
bond cleavage and catalytic diversiWcation within the HAD
enzyme superfamily. Biochemistry 39:10385–10396. doi:10.1021/
bi001171j
Morisseau C, Hammock BD (2005) Epoxide hydrolases: mechanisms,
inhibitor designs, and biological roles. Annu Rev Pharmacol
Toxicol 45:311–333. doi:10.1146/annurev.pharmtox.45.120403.
095920
Morisseau C, Du G, Newman JW, Hammock BD (1998) Mechanism
of mammalian soluble epoxide hydrolase inhibition by chalcone
oxide derivatives. Arch Biochem Biophys 356:214–228.
doi:10.1006/abbi.1998.0756
Morisseau C, Newman JW, Dowdy DL, Goodrow MH, Hammock BD
(2001) Inhibition of microsomal epoxide hydrolases by ureas,
amides, and amines. Chem Res Toxicol 14:409–415. doi:10.1021/
tx0001732
Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL,
Hammock BD (2002) Structural reWnement of inhibitors of
urea-based soluble epoxide hydrolases. Biochem Pharmacol
63:1599–1608. doi:10.1016/S0006-2952(02)00952-8
Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD
(2006) Peptidyl-urea based inhibitors of soluble epoxide hydro-
lases. Bioorg Med Chem Lett 16:5439–5444. doi:10.1016/
j.bmcl.2006.07.073
Morisseau C, Newman JW, Wheelock CE, Hill Iii T, Morin D,
Buckpitt AR, Hammock BD (2008) Development of metaboli-
cally stable inhibitors of Mammalian microsomal epoxide hydro-
lase. Chem Res Toxicol 21:951–957. doi:10.1021/tx700446u
Mowbray SL, Elfstrom LT, Ahlgren KM, Andersson CE, Widersten M
(2006) X-ray structure of potato epoxide hydrolase sheds light on
substrate speciWcity in plant enzymes. Protein Sci 15:1628–1637.
doi:10.1110/ps.051792106
Mrsny RJ, Gewirtz AT, Siccardi D, Savidge T, Hurley BP, Madara JL,
McCormick BA (2004) IdentiWcation of hepoxilin A3 in inXam-
matory events: a required role in neutrophil migration across
intestinal epithelia. Proc Natl Acad Sci USA 101:7421–7426.
doi:10.1073/pnas.0400832101
Mullen RT, Trelease RN, Duerk H, Arand M, Hammock BD, Oesch F,
Grant DF (1999) DiVerential subcellular localization of endoge-
nous and transfected soluble epoxide hydrolase in mammalian
cells: evidence for isozyme variants. FEBS Lett 445:301–305.
doi:10.1016/S0014-5793(99)00142-8
Muller F, Arand M, Frank H, Seidel A, Hinz W, Winkler L, Hanel K,
Blee E, Beetham JK, Hammock BD, Oesch F (1997) Visualiza-
tion of a covalent intermediate between microsomal epoxide
hydrolase, but not cholesterol epoxide hydrolase, and their sub-
strates. Eur J Biochem 245:490–496. doi:10.1111/j.1432-1033.
1997.00490.x
Nakanishi H, Suda T, Katoh M, Watanabe A, Igishi T, Kodani M,
Matsumoto S, Nakamoto M, Shigeoka Y, Okabe T, Oshimura M,
Shimizu E (2004) Loss of imprinting of PEG1/MEST in lung can-
cer cell lines. Oncol Rep 12:1273–1278
Nardini M, Ridder IS, Rozeboom HJ, Kalk KH, Rink R, Janssen DB,
Dijkstra BW (1999) The x-ray structure of epoxide hydrolase
from Agrobacterium radiobacter AD1. An enzyme to detoxify
harmful epoxides. J Biol Chem 274:14579–14586. doi:10.1074/
jbc.274.21.14579
Newman JW, Morisseau C, Harris TR, Hammock BD (2003) The sol-
uble epoxide hydrolase encoded by EPXH2 is a bifunctional
enzyme with novel lipid phosphate phosphatase activity. Proc
Natl Acad Sci USA 100:1558–1563. doi:10.1073/pnas.0437724100
Newman JW, Morisseau C, Hammock BD (2005) Epoxide hydrolases:
their roles and interactions with lipid metabolism. Prog Lipid Res
44:1–51. doi:10.1016/j.plipres.2004.10.001
Nigam S, ZaWriou MP, Deva R, Ciccoli R, Roux-Van der Merwe R
(2007) Structure, biochemistry and biology of hepoxilins: an
update. FEBS J 274:3503–3512. doi:10.1111/j.1742-4658.2007.
05910.x
Nikonova L, Koza RA, Mendoza T, Chao PM, Curley JP, Kozak LP
(2008) Mesoderm-speciWc transcript is associated with fat mass
expansion in response to a positive energy balance. FASEB J
22:3925–3937. doi:10.1096/fj.08-108266
Oesch F (1973) Mammalian epoxide hydrolases: inducible enzymes
catalysing the inactivation of carcinogenic and cytotoxic
316 Arch Toxicol (2009) 83:297–318
123
metabolites derived from aromatic and oleWnic compounds.
Xenobiotica 3:305–340
Oesch F (1974) PuriWcation and speciWcity of a human microsomal
epoxide hydratase. Biochem J 139:77–88
Oesch F, Timms CW, Walker CH, Guenthner TM, Sparrow A, Watabe
T, Wolf CR (1984) Existence of multiple forms of microsomal
epoxide hydrolases with radically diVerent substrate speciWcities.
Carcinogenesis 5:7–9. doi:10.1093/carcin/5.1.7
Oesch F, Schladt L, Hartmann R, Timms C, Worner W (1986) Rat
cytosolic epoxide hydrolase. Adv Exp Med Biol 197:195–201
Oesch F, Herrero ME, Hengstler JG, Lohmann M, Arand M (2000)
Metabolic detoxiWcation: implications for thresholds. Toxicol
Pathol 28:382–387. doi:10.1177/019262330002800305
Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhisa M,
Yamasaki Y (2005) Association of soluble epoxide hydrolase
gene polymorphism with insulin resistance in type 2 diabetic
patients. Biochem Biophys Res Commun 331:347–350.
doi:10.1016/j.bbrc.2005.03.171
Oliw EH, Guengerich FP, Oates JA (1982) Oxygenation of arachidonic
acid by hepatic monooxygenases. Isolation and metabolism of
four epoxide intermediates. J Biol Chem 257:3771–3781
Omiecinski CJ, Hassett C, Hosagrahara V (2000) Epoxide hydrolase—
polymorphism and role in toxicology. Toxicol Lett 112–113:365–
370. doi:10.1016/S0378-4274(99)00235-0
Pace-Asciak CR, Lee WS (1989) PuriWcation of hepoxilin epoxide
hydrolase from rat liver. J Biol Chem 264:9310–9313
Pace-Asciak CR, Martin JM (1984) Hepoxilin, a new family of insulin
secretagogues formed by intact rat pancreatic islets. Prostaglandins
Leukot Med 16:173–180. doi:10.1016/0262-1746(84)90069-6
Pace-Asciak CR, Laneuville O, Su WG, Corey EJ, Gurevich N, Wu P,
Carlen PL (1990) A glutathione conjugate of hepoxilin A3: for-
mation and action in the rat central nervous system. Proc Natl
Acad Sci USA 87:3037–3041. doi:10.1073/pnas.87.8.3037
Pace-Asciak CR, Reynaud D, Demin PM (1995) Hepoxilins: a review
on their enzymatic formation, metabolism and chemical synthe-
sis. Lipids 30:107–114. doi:10.1007/BF02538262
Papadopoulos D, Seidegard J, Georgellis A, Rydstrom J (1985) Sub-
cellular distribution, catalytic properties and partial puriWcation of
epoxide hydrolase in the human adrenal gland. Chem Biol Inter-
act 55:249–260. doi:10.1016/S0009-2797(85)80133-2
Pedersen IS, Dervan PA, Broderick D, Harrison M, Miller N, Delany
E, O’Shea D, Costello P, McGoldrick A, Keating G, Tobin B, Go-
rey T, McCann A (1999) Frequent loss of imprinting of PEG1/
MEST in invasive breast cancer. Cancer Res 59:5449–5451
Pinot F, Grant DF, Beetham JK, Parker AG, Borhan B, Landt S, Jones
AD, Hammock BD (1995) Molecular and biochemical evidence
for the involvement of the Asp-333-His-523 pair in the catalytic
mechanism of soluble epoxide hydrolase. J Biol Chem 270:7968–
7974. doi:10.1074/jbc.270.14.7968
Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiV JC (2003) 5,
6-Epoxyeicosatrienoic acid mediates the enhanced renal vasodi-
lation to arachidonic acid in the SHR. Hypertension 42:548–554.
doi:10.1161/01.HYP.0000090095.87899.36
Potente M, Fisslthaler B, Busse R, Fleming I (2003) 11, 12-Epoxyei-
cosatrienoic acid-induced inhibition of FOXO factors promotes
endothelial proliferation by down-regulating p27Kip1. J Biol
Chem 278:29619–29625. doi:10.1074/jbc.M305385200
Prestwich GD, Lucarelli I, Park SK, Loury DN, Moody DE, Hammock
BD (1985) Cyclopropyl oxiranes: reversible inhibitors of cyto-
solic and microsomal epoxide hydrolases. Arch Biochem Biophys
237:361–372. doi:10.1016/0003-9861(85)90288-7
Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenwe-
iser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah
AE, Zeldin DC, Grant DF (2003) Polymorphisms in human solu-
ble epoxide hydrolase. Mol Pharmacol 64:482–490. doi:10.1124/
mol.64.2.482
Raaka S, Hassett C, Omiencinski CJ (1998) Human microsomal
epoxide hydrolase: 5-Xanking region genetic polymorphisms.
Carcinogenesis 19:387–393. doi:10.1093/carcin/19.3.387
Radmark O, Shimizu T, Jornvall H, Samuelsson B (1984) Leukotriene
A4 hydrolase in human leukocytes. PuriWcation and properties.
J Biol Chem 259:12339–12345
Rappaport SM, Yeowell-O’Connell K, Bodell W, Yager JW, Syman-
ski E (1996) An investigation of multiple biomarkers among
workers exposed to styrene and styrene-7, 8-oxide. Cancer Res
56:5410–5416
Recio L, Bauer A, Faiola B (2005) Use of genetically modiWed mouse
models to assess pathways of benzene-induced bone marrow
cytotoxicity and genotoxicity. Chem Biol Interact 153–154:159–
164. doi:10.1016/j.cbi.2005.03.020
Reddy BS, Wynder EL (1977) Metabolic epidemiology of colon can-
cer. Fecal bile acids and neutral sterols in colon cancer patients
and patients with adenomatous polyps. Cancer 39:2533–2539.
doi:10.1002/1097-0142(197706)39:6<2533::AID-CNCR282039
0634>3.0.CO;2-X
Reynaud D, Demin PM, Sutherland M, Nigam S, Pace-Asciak CR
(1999) Hepoxilin signaling in intact human neutrophils: biphasic
elevation of intracellular calcium by unesteriWed hepoxilin A3.
FEBS Lett 446:236–238. doi:10.1016/S0014-5793(99)00225-2
Rigsby RE, Fillgrove KL, BeihoVer LA, Armstrong RN (2005) Fosfo-
mycin resistance proteins: a nexus of glutathione transferases and
epoxide hydrolases in a metalloenzyme superfamily. Methods
Enzymol 401:367–379. doi:10.1016/S0076-6879(05)01023-2
Rimner A, Al Makdessi S, Sweidan H, Wischhusen J, Rabenstein B,
Shatat K, Mayer P, Spyridopoulos I (2005) Relevance and mech-
anism of oxysterol stereospeciWcity in coronary artery disease.
Free Radic Biol Med 38:535–544. doi:10.1016/j.freeradbiomed.
2004.11.016
Ryan L, O’Callaghan YC, O’Brien NM (2004) Comparison of the
apoptotic processes induced by the oxysterols 7beta-hydroxycho-
lesterol and cholesterol-5beta, 6beta-epoxide. Cell Biol Toxicol
20:313–323. doi:10.1007/s10565-004-5066-7
Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y (2001) Sev-
enty genetic variations in human microsomal and soluble epoxide
hydrolase genes (EPHX1 and EPHX2) in the Japanese population.
J Hum Genet 46:325–329. doi:10.1007/s100380170067
Sandberg M, Meijer J (1996) Structural characterization of the human
soluble epoxide hydrolase gene (EPHX2). Biochem Biophys Res
Commun 221:333–339. doi:10.1006/bbrc.1996.0596
Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ (2000)
IdentiWcation and functional characterization of human soluble
epoxide hydrolase genetic polymorphisms. J Biol Chem
275:28873–28881. doi:10.1074/jbc.M001153200
Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, Umemura S,
Xin Y, Wu LL, Larrinaga-Shum S, Stephenson SH, Hunt SC,
Hopkins PN (2004) Soluble epoxide hydrolase variant
(Glu287Arg) modiWes plasma total cholesterol and triglyceride
phenotype in familial hypercholesterolemia: intrafamilial associ-
ation study in an eight-generation hyperlipidemic kindred. J Hum
Genet 49:29–34. doi:10.1007/s10038-003-0103-6
Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP,
Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic
target for acute inXammation. Proc Natl Acad Sci USA
102:9772–9777. doi:10.1073/pnas.0503279102
Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP,
Hammock BD (2006) Enhancement of antinociception by coad-
ministration of nonsteroidal anti-inXammatory drugs and soluble
epoxide hydrolase inhibitors. Proc Natl Acad Sci USA
103:13646–13651. doi:10.1073/pnas.0605908103
Selengut JD (2001) MDP-1 is a new and distinct member of the halo-
acid dehalogenase family of aspartate-dependent phosphohydro-
lases. Biochemistry 40:12704–12711. doi:10.1021/bi011405e
Arch Toxicol (2009) 83:297–318 317
123
Sevanian A, Peterson AR (1984) Cholesterol epoxide is a direct-acting
mutagen. Proc Natl Acad Sci USA 81:4198–4202. doi:10.1073/
pnas.81.13.4198
Sevanian A, Peterson AR (1986) The cytotoxic and mutagenic proper-
ties of cholesterol oxidation products. Food Chem Toxicol
24:1103–1110. doi:10.1016/0278-6915(86)90295-4
Shimada T (2006) Xenobiotic-metabolizing enzymes involved in
activation and detoxiWcation of carcinogenic polycyclic aro-
matic hydrocarbons. Drug Metab Pharmacokinet 21:257–276.
doi:10.2133/dmpk.21.257
Shkolnik K, Ben-Dor S, Galiani D, Hourvitz A, Dekel N (2007) A nov-
el ovary-speciWc and ovulation-associated variant of epoxide
hydrolase 2. FEBS Lett 581:4891–4898. doi:10.1016/j.febslet.
2007.09.016
Shou M, Gonzalez FJ, Gelboin HV (1996) Stereoselective epoxidation
and hydration at the K-region of polycyclic aromatic hydrocar-
bons by cDNA-expressed cytochromes P450 1A1, 1A2, and
epoxide hydrolase. Biochemistry 35:15807–15813. doi:10.1021/
bi962042z
Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ
(2000) Targeted disruption of soluble epoxide hydrolase reveals a
role in blood pressure regulation. J Biol Chem 275:40504–40510.
doi:10.1074/jbc.M008106200
Smit MS (2004) Fungal epoxide hydrolases: new landmarks in
sequence-activity space. Trends Biotechnol 22:123–129.
doi:10.1016/j.tibtech.2004.01.012
Smith CA, Harrison DJ (1997) Association between polymorphism in
gene for microsomal epoxide hydrolase and susceptibility to
emphysema. Lancet 350:630–633. doi:10.1016/S0140-6736(96)
08061-0
Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock
BD (2005) Attenuation of tobacco smoke-induced lung inXam-
mation by treatment with a soluble epoxide hydrolase inhibitor.
Proc Natl Acad Sci USA 102:2186–2191. doi:10.1073/pnas.
0409591102
Snider NT, Kornilov AM, Kent UM, Hollenberg PF (2007) Ananda-
mide metabolism by human liver and kidney microsomal cyto-
chrome p450 enzymes to form hydroxyeicosatetraenoic and
epoxyeicosatrienoic acid ethanolamides. J Pharmacol Exp Ther
321:590–597. doi:10.1124/jpet.107.119321
Snyder R, Chepiga T, Yang CS, Thomas H, Platt K, Oesch F (1993)
Benzene metabolism by reconstituted cytochromes P450 2B1 and
2E1 and its modulation by cytochrome b5, microsomal epoxide
hydrolase, and glutathione transferases: evidence for an important
role of microsomal epoxide hydrolase in the formation of hydro-
quinone. Toxicol Appl Pharmacol 122:172–181. doi:10.1006/
taap.1993.1185
Spector AA, Norris AW (2007) Action of epoxyeicosatrienoic acids on
cellular function. Am J Physiol Cell Physiol 292:C996–C1012.
doi:10.1152/ajpcell.00402.2006
Srivastava PK, Sharma VK, Kalonia DS, Grant DF (2004) Polymor-
phisms in human soluble epoxide hydrolase: eVects on enzyme
activity, enzyme stability, and quaternary structure. Arch Bio-
chem Biophys 427:164–169. doi:10.1016/j.abb.2004.05.003
Stansberg C, Vik-Mo AO, Holdhus R, Breilid H, Srebro B, Petersen K,
Jorgensen HA, Jonassen I, Steen VM (2007) Gene expression
proWles in rat brain disclose CNS signature genes and regional
patterns of functional specialisation. BMC Genomics 8:94.
doi:10.1186/1471-2164-8-94
Summerer S, Hanano A, Utsumi S, Arand M, Schuber F, Blee E (2002)
Stereochemical features of the hydrolysis of 9, 10-epoxystearic
acid catalysed by plant and mammalian epoxide hydrolases. Bio-
chem J 366:471–480. doi:10.1042/BJ20011778
Sumner SJ, Fennell TR (1994) Review of the metabolic fate of styrene.
Crit Rev Toxicol 24(1):S11–S33. doi:10.3109/104084494090
20138
Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK (2002) Inhi-
bition of vascular smooth muscle cell migration by cytochrome
p450 epoxygenase-derived eicosanoids. Circ Res 90:1020–1027.
doi:10.1161/01.RES.0000017727.35930.33
Sun Z, Sood S, Li N, Ramji D, Yang P, Newman RA, Yang CS, Chen
X (2006) Involvement of the 5-lipoxygenase/leukotriene A4
hydrolase pathway in 7, 12-dimethylbenz[a]anthracene (DMBA)-
induced oral carcinogenesis in hamster cheek pouch, and inhibi-
tion of carcinogenesis by its inhibitors. Carcinogenesis 27:1902–
1908. doi:10.1093/carcin/bgl039
Sura P, Sura R, Enayetallah AE, Grant DF (2008) Distribution and
expression of soluble epoxide hydrolase in human brain. J Histo-
chem Cytochem 56:551–559. doi:10.1369/jhc.2008.950659
Terashvili M, Tseng LF, Wu HE, Narayanan J, Hart LM, Falck JR,
Pratt PF, Harder DR (2008) Antinociception produced by 14,15-
epoxyeicosatrienoic acid is mediated by the activation of {beta}-
endorphin and Met-enkephalin in the rat ventrolateral periaqu-
eductal gray. J Pharmacol Exp Ther 326:614–622
Thunnissen MM, Nordlund P, Haeggstrom JZ (2001) Crystal structure
of human leukotriene A(4) hydrolase, a bifunctional enzyme in
inXammation. Nat Struct Biol 8:131–135. doi:10.1038/84117
Toulza E, Mattiuzzo NR, Galliano MF, Jonca N, Dossat C, Jacob D, de
Daruvar A, Wincker P, Serre G, Guerrin M (2007) Large-scale
identiWcation of human genes implicated in epidermal barrier
function. Genome Biol 8:R107. doi:10.1186/gb-2007-8-6-r107
Tran KL, Aronov PA, Tanaka H, Newman JW, Hammock BD, Moris-
seau C (2005) Lipid sulfates and sulfonates are allosteric compet-
itive inhibitors of the N-terminal phosphatase activity of the
mammalian soluble epoxide hydrolase. Biochemistry 44:12179–
12187. doi:10.1021/bi050842g
Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, Hunter DJ (2005)
Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smok-
ing, and risk of colorectal carcinoma in the Nurses’ Health Study
and the Physicians’ Health Study. Mol Carcinog 44:21–30.
doi:10.1002/mc.20112
Tsuge H, Ago H, Aoki M, Furuno M, Noma M, Miyano M, Minami M,
Izumi T, Shimizu T (1994) Crystallization and preliminary X-ray
crystallographic studies of recombinant human leukotriene A4
hydrolase complexed with bestatin. J Mol Biol 238:854–856.
doi:10.1006/jmbi.1994.1341
Tzeng HF, Laughlin LT, Armstrong RN (1998) Semifunctional site-
speciWc mutants aVecting the hydrolytic half-reaction of
microsomal epoxide hydrolase. Biochemistry 37:2905–2911.
doi:10.1021/bi9727388
van Bladeren PJ, Sayer JM, Ryan DE, Thomas PE, Levin W, Jerina
DM (1985) DiVerential stereoselectivity of cytochromes P-450b
and P-450c in the formation of naphthalene and anthracene 1, 2-
oxides. The role of epoxide hydrolase in determining the enantio-
mer composition of the 1, 2-dihydrodiols formed. J Biol Chem
260:10226–10235
van der Werf MJ, Overkamp KM, de Bont JA (1998) Limonene-1, 2-
epoxide hydrolase from Rhodococcus erythropolis DCL14 belongs
to a novel class of epoxide hydrolases. J Bacteriol 180:5052–5057
van Loo B, Kingma J, Arand M, Wubbolts MG, Janssen DB (2006)
Diversity and biocatalytic potential of epoxide hydrolases identi-
Wed by genome analysis. Appl Environ Microbiol 72:2905–2917.
doi:10.1128/AEM.72.4.2905-2917.2006
Vejux A, Kahn E, Menetrier F, Montange T, Lherminier J, Riedinger
JM, Lizard G (2007) Cytotoxic oxysterols induce caspase-inde-
pendent myelin Wgure formation and caspase-dependent polar lip-
id accumulation. Histochem Cell Biol 127:609–624. doi:10.1007/
s00418-006-0268-0
von Dippe P, Zhu QS, Levy D (2003) Cell surface expression and bile
acid transport function of one topological form of m-epoxide
hydrolase. Biochem Biophys Res Commun 309:804–809.
doi:10.1016/j.bbrc.2003.08.074
318 Arch Toxicol (2009) 83:297–318
123
Wang W, Kim R, Jancarik J, Yokota H, Kim SH (2001) Crystal struc-
ture of phosphoserine phosphatase from Methanococcus janna-
schii, a hyperthermophile, at 1.8 A resolution. Structure 9:65–71.
doi:10.1016/S0969-2126(00)00558-X
Wang W, Cho HS, Kim R, Jancarik J, Yokota H, Nguyen HH, Grigo-
riev IV, Wemmer DE, Kim SH (2002) Structural characterization
of the reaction pathway in phosphoserine phosphatase: crystallo-
graphic “snapshots” of intermediate states. J Mol Biol 319:421–
431. doi:10.1016/S0022-2836(02)00324-8
Watabe T, Kanai M, Isobe M, Ozawa N (1981) The hepatic micro-
somal biotransformation of delta 5-steroids to 5 alpha, 6 beta-gly-
cols via alpha- and beta-epoxides. J Biol Chem 256:2900–2907
Watabe T, Ozawa N, Ishii H, Chiba K, Hiratsuka A (1986) Hepatic
microsomal cholesterol epoxide hydrolase: selective inhibition by
detergents and separation from xenobiotic epoxide hydrolase.
Biochem Biophys Res Commun 140:632–637. doi:10.1016/
0006-291X(86)90778-3
WickliVe JK, Herring SM, Hallberg LM, Galbert LA, Masters OEIII,
Ammenheuser MM, Xie J, Friedberg EC, Lloyd RS, Abdel-Rah-
man SZ, Ward JB Jr (2007) DetoxiWcation of oleWnic epoxides
and nucleotide excision repair of epoxide-mediated DNA dam-
age: Insights from animal models examining human sensitivity to
1, 3-butadiene. Chem Biol Interact 166:226–231. doi:10.1016/
j.cbi.2006.04.017
Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, Whittle
H, Kirk GD, Hall AJ (2000) Environmental and genetic determi-
nants of aXatoxin-albumin adducts in the Gambia. Int J Cancer
86:1–7. doi:10.1002/(SICI)1097-0215(20000401)86:1<1::AID-
IJC1>3.0.CO;2-I
Wilson AM, Sisk RM, O’Brien NM (1997) Modulation of cholestane-
3 beta, 5 alpha, 6 beta-triol toxicity by butylated hydroxytoluene,
alpha-tocopherol and beta-carotene in newborn rat kidney cells in
vitro. Br J Nutr 78:479–492. doi:10.1079/BJN19970165
Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T
(2006) Chemical genomic screening for methylation-silenced
genes in gastric cancer cell lines using 5-aza-2-deoxycytidine
treatment and oligonucleotide microarray. Cancer Sci 97:64–71.
doi:10.1111/j.1349-7006.2006.00136.x
Yu Z, Schneider C, Boeglin WE, Brash AR (2007) Epidermal lipoxy-
genase products of the hepoxilin pathway selectively activate the
nuclear receptor PPARalpha. Lipids 42:491–497. doi:10.1007/
s11745-007-3054-4
Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snap-
per JR, Capdevila JH (1993) Regio- and enantiofacial selectivity
of epoxyeicosatrienoic acid hydration by cytosolic epoxide
hydrolase. J Biol Chem 268:6402–6407
Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock
BD, Wu S (1996) Biochemical characterization of the human liv-
er cytochrome P450 arachidonic acid epoxygenase pathway. Arch
Biochem Biophys 330:87–96. doi:10.1006/abbi.1996.0229
Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C,
Luria A, Hammock BD, Falck JR, Alkayed NJ (2007) Soluble
epoxide hydrolase: a novel therapeutic target in stroke. J Cereb
Blood Flow Metab 27:1931–1940. doi:10.1038/sj.jcbfm.9600494
Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC,
Wang DW (2008a) Genetic variation in cytochrome P450 2J2 and
soluble epoxide hydrolase and risk of ischemic stroke in a
Chinese population. Pharmacogenet Genomics 18:45–51.
doi:10.1097/FPC.0b013e3282f313e8
Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, IliV JJ, DeBarber
AE, Koop DR, Alkayed NJ (2008b) Soluble epoxide hydrolase
gene deletion is protective against experimental cerebral ischemia.
Stroke 39:2073–2078. doi:10.1161/STROKEAHA.107.508325
Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock
BD, Stewart J, Pollock JS, Pollock DM, Imig JD (2004) Soluble
epoxide hydrolase inhibition protects the kidney from hyperten-
sion-induced damage. J Am Soc Nephrol 15:1244–1253
Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB (2007) Suppression
of 5-lipoxygenase gene is involved in triptolide-induced apopto-
sis in pancreatic tumor cell lines. Biochim Biophys Acta
1770:1021–1027
Zhu QS, Qian B, Levy D (2004) Regulation of human microsomal
epoxide hydrolase gene (EPHX1) expression by the transcription
factor GATA-4. Biochim Biophys Acta 1676:251–260
Zou J, Hallberg BM, Bergfors T, Oesch F, Arand M, Mowbray SL,
Jones TA (2000) Structure of Aspergillus niger epoxide hydrolase
at 1.8 A resolution: implications for the structure and function of
the mammalian microsomal class of epoxide hydrolases.
Structure 8:111–122. doi:10.1016/S0969-2126(00)00087-3
Zusterzeel PL, Peters WH, Visser W, Hermsen KJ, Roelofs HM,
Steegers EA (2001) A polymorphism in the gene for microsomal
epoxide hydrolase is associated with pre-eclampsia. J Med Genet
38:234–237. doi:10.1136/jmg.38.4.234
